Navbar

Guidelines
Compendia & Templates
Education & Research
Patient Resources
Business & Policy
Global

Guidelines Firewall Policy Treatment by Cancer Type Detection, Prevention, and Risk Reduction Supportive Care Specific Populations Guidelines for Patients Guidelines With Evidence Blocks NCCN Framework For Resource Stratification Harmonized Guidelines International Adaptations and Translations NCCN Mobile Apps Guidelines Process Guidelines Panels and Disclosure Permission to Cite or Use NCCN Content Recently Updated Guidelines Submission Request to the Guidelines Panels Order Free Print Copies

Acute Lymphoblastic Leukemia Acute Myeloid Leukemia Ampullary Adenocarcinoma Anal Carcinoma Basal Cell Skin Cancer B-Cell Lymphomas Biliary Tract Cancers Bladder Cancer Bone Cancer Breast Cancer Castleman Disease Central Nervous System Cancers Cervical Cancer Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Chronic Myeloid Leukemia Colon Cancer Dermatofibrosarcoma Protuberans Esophageal and Esophagogastric Junction Cancers Gastric Cancer Gastrointestinal Stromal Tumors Gestational Trophoblastic Neoplasia Hairy Cell Leukemia Head and Neck Cancers

Hepatobiliary Cancers Hepatocellular Carcinoma Histiocytic Neoplasms Hodgkin Lymphoma Kaposi Sarcoma Kidney Cancer Melanoma: Cutaneous Melanoma: Uveal Merkel Cell Carcinoma Mesothelioma: Peritoneal Mesothelioma: Pleural Multiple Myeloma Myelodysplastic Syndromes Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Gene Fusions Myeloproliferative Neoplasms Neuroblastoma Neuroendocrine and Adrenal Tumors Non-Small Cell Lung Cancer Occult Primary Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer Pancreatic Adenocarcinoma Pediatric Acute Lymphoblastic Leukemia Pediatric Aggressive Mature B-Cell Lymphomas

Pediatric Central Nervous System Cancers Pediatric Hodgkin Lymphoma Penile Cancer Primary Cutaneous Lymphomas Prostate Cancer Rectal Cancer Small Bowel Adenocarcinoma Small Cell Lung Cancer Soft Tissue Sarcoma Squamous Cell Skin Cancer Systemic Light Chain Amyloidosis Systemic Mastocytosis T-Cell Lymphomas Testicular Cancer Thymomas and Thymic Carcinomas Thyroid Carcinoma Uterine Neoplasms Vaginal Cancer Vulvar Cancer Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma Wilms Tumor (Nephroblastoma)

Breast Cancer Risk Reduction Breast Cancer Screening and Diagnosis Colorectal Cancer Screening

Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate Genetic/Familial High-Risk Assessment: Colorectal, Endometrial, and Gastric Lung Cancer Screening

Prostate Cancer Early Detection

Adult Cancer Pain Antiemesis Cancer-Associated Venous Thromboembolic Disease Cancer-Related Fatigue

Distress Management Hematopoietic Cell Transplantation Hematopoietic Growth Factors Management of Immunotherapy-Related Toxicities

Palliative Care Prevention and Treatment of Cancer-Related Infections Smoking Cessation Survivorship

Adolescent and Young Adult (AYA) Oncology

Cancer in People with HIV

Older Adult Oncology

Acute Lymphoblastic Leukemia (adult) Acute Lymphoblastic Leukemia in Children Acute Myeloid Leukemia Adolescent and Young Adult Cancer Adrenal Tumors Anal Cancer Anemia and Neutropenia - Low Blood Cell Counts Basal Cell Skin Cancer Bladder Cancer Blood Clots and Cancer Bone Cancer Brain Cancer - Glioma Breast Cancer - Ductal Carcinoma In Situ Breast Cancer - Inflammatory Breast Cancer Breast Cancer - Invasive Breast Cancer Breast Cancer - Metastatic Breast Cancer Breast Cancer Screening and Diagnosis Cervical Cancer Chronic Lymphocytic Leukemia Chronic Myeloid Leukemia Colon Cancer Colorectal Cancer Screening Cutaneous B-Cell Lymphomas Cutaneous T-Cell Lymphomas Diffuse Large B-Cell Lymphomas

Distress During Cancer Care Esophageal Cancer Fatigue and Cancer Follicular Lymphoma Gallbladder and Bile Duct Cancers Gastrointestinal Stromal Tumors (GIST) Genetic Testing for Hereditary Breast, Ovarian, Pancreatic, and Prostate Cancers Graft-Versus-Host Disease Hodgkin Lymphoma in Adults Hodgkin Lymphoma in Children Immunotherapy Side Effects: CAR T-Cell Therapy Immunotherapy Side Effects: Immune Checkpoint Inhibitors Kidney Cancer Liver Cancer Lung Cancer Screening Mantle Cell Lymphoma Marginal Zone Lymphomas Melanoma Mesothelioma: Pleural - Malignant Pleural Mesothelioma Mouth Cancer Multiple Myeloma Myelodysplastic Syndromes Myeloproliferative Neoplasms Nasopharyngeal Cancer Nausea and Vomiting

Neuroendocrine Tumors Non-Small Cell Lung Cancer - Early and Locally Advanced Non-Small Cell Lung Cancer - Metastatic Ovarian Cancer Palliative Care Pancreatic Cancer Peripheral T-Cell Lymphoma Primary Central Nervous System Lymphoma Prostate Cancer: Advanced Stage Prostate Cancer: Early Stage Quitting Smoking Rectal Cancer Small Bowel Adenocarcinoma Small Cell Lung Cancer Soft Tissue Sarcoma Squamous Cell Skin Cancer Stomach Cancer Survivorship Care for Cancer-Related Late and Long-Term Effects Survivorship Care for Healthy Living Systemic Mastocytosis Throat Cancer Thyroid Cancer Uterine Cancer Waldenström Macroglobulinemia

About Clinical Practice Guidelines Development and Update of Guidelines

Transparency Process Guidelines Panels Meeting Schedule

Firewall Policy

Disclosure Policies and Potential Conflicts of Interest

Guidelines Panels

Guideline Steering Committee

Submission Request History

My Submission Request

Submission Request Form

Compendia & Templates Compendia Chemotherapy Order Templates

NCCN Compendia Drugs and Biologics Compendium

Biomarkers Compendium Imaging AUC Compendium

Radiation Therapy Compendium Subscribe to NCCN Compendium

Browse by Cancer Type View Chemotherapy Order Templates User Guide

EHR Integration Chemotherapy Order Templates Committee

Subscribe to NCCN Templates Chemotherapy Order Templates Reviewer Acknowledgement

Education & Research NCCN Continuing Education Events and Programs Oncology Research Program JNCCN Publications

Continuing Education (CE)

NCCN Continuing Education Portal

NCCN Guidelines in Practice™

Calendar of Events Annual Conference Annual Conference Press Coverage

Nursing Events Share that You are Attending an NCCN Event Annual Congress: Hematologic Malignancies

2025 Hematologic Malignancies Congress Exhibitor Prospectus

Oncology Research Program (ORP) Current Opportunities ORP Recent News ORP Grant History

Scientific Publications Clinical Trials Young Investigator Awards Informed Consent Language Database

Best Practices for Biorepositories Shared Resources Disclosure Policy

About JNCCN

Subscribe to JNCCN

JNCCN Email Updates

Business & Policy Business Policy and Advocacy Program

Corporate Council Academy Trends U.S. Surveys Trends Global Surveys Flash Updates

Order Free Pocket Guidelines and Patient Guidelines Support Opportunities Advertising Opportunities Research Tools: REMS Employer Resources

Virtual Reimbursement Resource Room and App Health Information Technology Licenses Embargo Policy Firewall Policy

Policy and Advocacy Program Policy Priorities NCCN Findings on Cancer Drug Shortages

Advancing Cancer Equity The Alliance for Cancer Care Equity (ACCE) Oncology Policy Summits

State Oncology Society Forum

Global Global Program Global Clinical Resources Global Support Opportunities Global Policy Contact NCCN Global

Africa Asia

Europe Latin America

Middle East & North Africa Worldwide

Clinical Guidelines Translations Guidelines for Patients Translations Distress Thermometer Tool Translations

International Adaptations Framework for Resource Stratification Harmonized Guidelines

Test - Adaptations & Harmonizations

Global Corporate Council Global Academy

Trends Global Surveys eBulletin Global Edition

Home
Guidelines
Submission Request to the Guidelines Panels
Submission Request History

Submission Request History

Firewall Policy
Treatment by Cancer Type
Detection, Prevention, and Risk Reduction
Supportive Care
Specific Populations
Guidelines for Patients
Guidelines With Evidence Blocks
NCCN Framework For Resource Stratification
Harmonized Guidelines
International Adaptations and Translations
NCCN Mobile Apps
Guidelines Process
Guidelines Panels and Disclosure
Permission to Cite or Use NCCN Content
Recently Updated Guidelines
Submission Request to the Guidelines Panels
Order Free Print Copies

Acute Lymphoblastic Leukemia Panel

clonoSEQ Submitted by Adaptive Biotechnologies on 10/27/2020
Blinatumomab Submitted by Amgen Inc. on 12/10/2020
blinatumomab Submitted by Amgen Inc. on 03/10/2021
Asparaginase erwinia chrysanthemi (recombinant) Submitted by Jazz Pharmaceuticals Inc. on 07/02/2021
Tecartus Submitted by Kite on 10/20/2021
MRD Submitted by Adaptive Biotechnologies on 10/22/2021
Ponatinib Submitted by Takeda Oncology on 10/28/2021
IV cetirizine Submitted by TerSera Therapeutics on 11/09/2021
Glucarpidase/use of MTXPK.org Submitted by BTG International on 05/26/2022
Asparaginase erwinia chrysanthemi (recombinant)-rywn Submitted by Jazz Pharmaceuticals Inc. on 08/19/2022
Remote Continuous Temperature Monitoring Submitted by Blue Spark Technologies on 09/20/2022
ponatinib + blinatumomab Submitted by Takeda Oncology on 09/30/2022
Inotuzumab ozogamicin Submitted by Pfizer Inc. on 10/03/2022
Blinatumomab Submitted by Amgen Inc. on 02/01/2023
Omidubicel-onlv Submitted by Gamida Cell, Inc on 04/28/2023
Continuous temperature monitoring Submitted by Blue Spark Technologies on 09/18/2023
inotuzumab ozogamicin Submitted by Pfizer Inc. on 10/30/2023
inotuzumab ozogamicin Submitted by Pfizer Inc. on 10/30/2023

Acute Myeloid Leukemia Panel

Venetoclax Submitted by AbbVie, Inc. on 06/26/2020
CC-486 Submitted by Bristol-Myers Squibb Company on 07/07/2020
Venetoclax + HMAs Submitted by AbbVie, Inc. on 08/14/2020
Azacitidine Submitted by Bristol-Myers Squibb Company on 09/01/2020
Venetoclax Submitted by AbbVie, Inc. and Genentech, Inc. on 01/25/2021
Sorafenib Submitted by Anticancer Fund on 04/07/2021
Venetoclax Submitted by AbbVie, Inc. on 02/15/2023
Daunorubicin and cytarabine Submitted by Jazz Pharmaceuticals Inc. on 03/21/2023
APL Differentiation Syndrome Submitted by Blue Spark Technologies on 03/23/2023
Avapritinib Submitted by Blueprint Medicines on 04/04/2023
Omidubicel-onlv Submitted by Gamida Cell, Inc on 04/27/2023

Adolescent and Young Adult Oncology Panel

Sodium Thiosulfate Submitted by Fennec Pharma on 12/02/2022

Adult Cancer Pain Panel

Polymerized Cross-linked Sucralfate Submitted by MMI Script Hub and Medical Supplies on 06/18/2020
Algorithm & Discussion Changes Submitted by Society of Interventional Oncology on 08/11/2020
Intravenous patient controlled analgesia Submitted by Fujian Cancer Hospital on 06/19/2022
IV cetirizine Submitted by TerSera Therapeutics on 06/28/2023

Antiemesis Panel

Akynzeo Submitted by Helsinn Healthcare SA on 08/24/2021
AKYNZEO Submitted by Helsinn Therapeutics, Inc. on 07/26/2023
Zolbetuximab Submitted by Astellas Pharma Global Development on 01/20/2025

B-Cell Lymphomas Panel

Tazemetostat Submitted by Epizyme Inc. on 06/18/2020
Selinexor Submitted by Karyopharm Therapeutics on 06/23/2020
Brexucabtagene Autoleucel Submitted by Kite on 07/24/2020
Tafasitamab-cxix in combo with Lenalidomide Submitted by Incyte Corporation and MorphoSys AG on 08/03/2020
NGS clarification Submitted by Adaptive Biotechnologies on 09/01/2020
Siltuximab Submitted by Castleman Disease Collaborative Network (CDCN) on 09/08/2020
Axicabtagene ciloleucel Submitted by Kite on 09/18/2020
Axicabtagene ciloleucel Submitted by Kite on 12/08/2020
Lisocabtagene maraleucel Submitted by Bristol-Myers Squibb Company on 02/08/2021
Umbralisib Submitted by TG Therapeutics, Inc. on 02/09/2021
Umbralisib Submitted by TG Therapeutics, Inc. on 02/10/2021
Umbralisib Submitted by TG Therapeutics, Inc. on 03/12/2021
Loncastuximab tesirine‐lpyl Submitted by ADC Therapeutics on 04/23/2021
Umbralisib Submitted by TG Therapeutics, Inc. on 05/19/2021
Measurable Residual Disease (MRD) Testing in Mantle Cell Lymphoma and Diffuse Large B Cell Lymphoma Submitted by Adaptive Biotechnologies on 08/23/2021
Tafasitamab-cxix Submitted by Dr. Wei Jiang, PhD and Dr. Michael Cuozzo, PharmD on 09/01/2021
Zanubrutinib Submitted by BeiGene, Ltd. on 09/15/2021
Zanubrutinib Submitted by BeiGene, Ltd. on 09/17/2021
Axicabtagene Ciloleucel Submitted by Kite on 12/12/2021
Axicabtagene Ciloleucel Submitted by Kite on 12/12/2021
polatuzumab vedotin-piiq Submitted by Genentech, Inc. on 12/15/2021
Duvelisib Submitted by Secura Bio, Inc. on 01/10/2022
obinuzutuzumab Submitted by Genentech, Inc. on 02/14/2022
lisocabtagene maraleucel; liso-cel Submitted by Bristol-Myers Squibb Company on 04/05/2022
glucarpidase Submitted by BTG International on 05/20/2022
Tisagenlecleucel Submitted by Novartis Pharmaceuticals Corporation on 06/01/2022
zanubrutinib Submitted by BeiGene, Ltd. on 06/06/2022
zanubrutinib Submitted by BeiGene, Ltd. on 06/06/2022
lisocabtagene maraleucel; liso-cel Submitted by Bristol-Myers Squibb Company on 06/13/2022
Lisocabtagene maraleucel Submitted by Bristol-Myers Squibb Company on 06/21/2022
Lisocabtagene maraleucel Submitted by Bristol-Myers Squibb Company on 06/24/2022
ibrutinib Submitted by Pharmacyclics, LLC on 06/30/2022
lisocabtagene maraleucel; liso-cel Submitted by Bristol-Myers Squibb Company on 08/04/2022
acalabrutinib Submitted by AstraZeneca on 08/15/2022
acalabrutinib + acid-reducing agents Submitted by AstraZeneca on 09/01/2022
Lisocabtagene maraleucel Submitted by Bristol-Myers Squibb Company on 12/19/2022
Ibrutinib Submitted by AbbVie, Inc. and Pharmacyclics, LLC on 12/19/2022
Lisocabtagene maraleucel Submitted by Bristol-Myers Squibb Company on 01/05/2023
Pirtobrutinib Submitted by Eli Lilly and Company on 01/27/2023
Epcoritamab-bysp Submitted by AbbVie, Inc. and Genmab US, Inc on 05/22/2023
Glofitamab-gxbm Submitted by Genentech, Inc. on 06/16/2023
Acalabrutinib + rituximab Submitted by AstraZeneca on 07/11/2023
Zanubrutinib Submitted by BeiGene, Ltd. on 08/01/2023
Castleman Disease Submitted by Castleman Disease Collaborative Network (CDCN) on 08/15/2023
Brexucabtagene autoleucel Submitted by Kite on 08/25/2023
Lisocabtagene Maraleucel Submitted by BMS on 04/03/2024
Lisocabtagene Maraleucel Submitted by BMS on 04/03/2024

Bladder/Penile Cancers Panel

Pembrolizumab Submitted by Merck & Co., Inc. on 06/17/2020
Avelumab Submitted by EMD Serono and Pfizer Inc. on 06/30/2020
Patient Advocate Recommendations Submitted by Bladder Cancer Advocacy Network (BCAN) on 07/27/2020
Urothelial tumor markers Submitted by Pacific Edge Diagnostics USA, Ltd. on 08/13/2020
Comprehensive genomic profiling Submitted by Foundation Medicine, Inc. on 08/28/2020
Avelumab Submitted by EMD Serono and Pfizer Inc. on 09/18/2020
Enfortumab vedotin Submitted by Seagen Inc on 02/16/2021
Atezolizumab Submitted by Genentech, Inc. on 03/08/2021
Sacituzumab govitecan-hziy Submitted by Gilead Sciences, Inc. on 04/15/2021
Nivolumab Submitted by Bristol-Myers Squibb Company on 06/03/2021
Enfortumab vedotin-ejfv Submitted by Seagen Inc on 07/13/2021
Nivolumab Submitted by Bristol-Myers Squibb Company on 08/20/2021
CGP Submitted by Guardant Health on 06/22/2022
TMB Submitted by Cleveland Clinic on 07/25/2022
TMB Submitted by Foundation Medicine, Inc. on 07/25/2022
Cabo Submitted by Exelixis Inc. on 10/04/2022
Nadofaragene firadenovec Submitted by Ferring Pharmaceuticals on 12/16/2022
Pembrolizumab Footnote Submitted by Merck & Co., Inc. on 02/17/2023
pembrolizumab in combination with enfortumab vedotin-ejfv Submitted by Merck & Co., Inc. on 04/04/2023
Nivolumab Submitted by Bristol-Myers Squibb Company on 05/02/2023
HER2 Submitted by Daiichi-Sankyo, Inc. on 06/06/2023
Cxbladder Triage Submitted by Pacific Edge Diagnostics USA, Ltd. on 07/11/2023
durvalumab Submitted by AstraZeneca on 07/18/2023
Sacituzumab govitecan-hziy Submitted by Gilead Sciences, Inc. on 07/19/2023
CtDNA Submitted by Natera, Inc. on 07/24/2023
Pembrolizumab + enfortumab vedotin-ejfv Submitted by Pfizer and Astellas Pharma Inc. on 12/15/2023
erdafitinib Submitted by JnJ on 12/18/2023
Pembrolizumab + enfortumab vedotin-ejfv Submitted by Merck & Co., Inc. on 12/18/2023
Enfortumab vedotin-ejfv Submitted by Pfizer and Astellas Pharma Inc. on 03/06/2024
Nivolumab Submitted by BMS on 03/07/2024
Fam-Trastuzumab Deruxtecan-nxki Submitted by Daiichi Sankyo, Inc. and AstraZeneca on 04/08/2024
Fam-Trastuzumab Deruxtecan-nxki Submitted by Daiichi Sankyo, Inc. and AstraZeneca on 04/08/2024
Fam-Trastuzumab Deruxtecan-nxki Submitted by Daiichi Sankyo, Inc. and AstraZeneca on 04/08/2024

Bone Cancer Panel

Tumor Mutational Burden (TMB) Submitted by Foundation Medicine, Inc. on 06/24/2020
Tumor Mutational Burden (TMB) Submitted by Foundation Medicine, Inc. on 09/18/2020
Comprehensive genomic profiling (CGP) Submitted by Foundation Medicine, Inc. on 04/15/2021
Comprehensive genomic profiling (CGP) Submitted by Illumina Inc. on 04/27/2021
Include nivolumab in combination with ipilimumab. Submitted by Bristol-Myers Squibb Company on 04/11/2022
Submission to include lurbinectedin for Ewing sarcoma Submitted by Jazz Pharmaceuticals Inc. on 07/29/2022
Selpercatinib Submitted by Eli Lilly and Company on 09/21/2022
Comprehensive genomic profiling (CGP) Submitted by Foundation Medicine, Inc. on 04/20/2023
OncoKB Submitted by Memorial Sloan Kettering Cancer Center on 05/11/2023
Glucarpidase Submitted by SERB Pharmaceuticals and BTG International on 01/04/2024
Repotrectinib Submitted by BMS on 06/14/2024
Repotrectinib Submitted by BMS on 06/14/2024
Repotrectinib Submitted by BMS on 06/14/2024

Breast Cancer Panel

Pembrolizumab Submitted by Merck & Co., Inc. on 05/29/2020
Pembrolizumab Submitted by Merck & Co., Inc. on 06/17/2020
TMB testing Submitted by Foundation Medicine, Inc. on 06/22/2020
Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf Submitted by Genentech, Inc. on 06/29/2020
Ado-trastuzumab emtansine Submitted by Linda W. Wilson, MD on 07/08/2020
Radiation Therapy Submitted by American Society for Radiation Oncology on 07/20/2020
21-Gene RT-PCR assay Submitted by Exact Sciences Inc. on 07/28/2020
FES PET Submitted by Zionexa on 07/29/2020
PET/CT Submitted by Society of Interventional Oncology on 07/30/2020
EndoPredict Submitted by Myriad Genetic Laboratories, Inc. on 08/01/2020
PET/CT Submitted by MD Anderson Cancer Center on 08/04/2020
Pertuzumab + ado-trastuzumab emtansine Submitted by Genentech, Inc. on 08/05/2020
Breast Cancer Index Submitted by Biotheranostics on 08/05/2020
Breast Cancer Index Submitted by Biotheranostics on 08/05/2020
L-Dex Submitted by ImpediMed, Inc. on 08/05/2020
Neratinib Submitted by Puma Biotechnology on 08/05/2020
NGS assay Submitted by Guardant Health on 08/06/2020
NGS assay Submitted by Foundation Medicine, Inc. on 08/06/2020
TMB testing Submitted by Foundation Medicine, Inc. on 09/15/2020
Neratinib Submitted by Puma Biotechnology on 10/05/2020
Pembrolizumab Submitted by Merck & Co., Inc. on 11/16/2020
Atezolizumab + albumin-bound paclitaxel Submitted by Genentech, Inc. on 12/02/2020
Capecitabine Submitted by Sun Yat-sen University Cancer Center on 01/29/2021
Atezolizumab Submitted by Genentech, Inc. on 03/16/2021
Sacituzumab govitecan-hziy Submitted by Gilead Sciences, Inc. on 04/08/2021
Olaparib Submitted by AstraZeneca on 04/12/2021
Sacituzumab govitecan-hziy Submitted by Gilead Sciences, Inc. on 04/26/2021
Capecitabine Submitted by Sun Yat-sen University Cancer Center on 05/21/2021
Comprehensive Genomic Profiling Submitted by Illumina Inc. on 05/26/2021
Olaparib Submitted by AstraZeneca on 06/09/2021
Cabazitaxel Submitted by Sanofi on 06/11/2021
Durvalumab Submitted by AstraZeneca on 07/01/2021
Neratinib Submitted by Puma Biotechnology on 07/07/2021
Larotrectinib Submitted by Bayer HealthCare on 07/08/2021
Guardant360 CDx Submitted by Guardant Health on 07/12/2021
APBI Dosing Submitted by Schwartzberg Center for Minimally Invasive Breast Surgery on 07/13/2021
Vaginal pH modulator Submitted by Evofem Biosciences, Inc. on 07/13/2021
Comprehensive Genomic Profiling Submitted by Foundation Medicine, Inc. on 07/15/2021
Tucatinib Submitted by Seagen Inc on 07/15/2021
Neratinib Submitted by Puma Biotechnology on 07/18/2021
Olaparib Submitted by AstraZeneca on 07/20/2021
12-Gene (EndoPredict) Assay Submitted by Myriad Genetic Laboratories, Inc. on 07/20/2021
Pembrolizumab Submitted by Merck & Co., Inc. on 07/27/2021
ctDNA Submitted by Natera, Inc. on 07/28/2021
ctDNA Submitted by Natera, Inc. on 07/28/2021
Dostarlimab-gxly Submitted by GlaxoSmithKline on 08/17/2021
Atezolizumab Submitted by Genentech, Inc. on 08/27/2021
Sacituzumab govitecan-hziy Submitted by Gilead Sciences, Inc. on 09/02/2021
Sacituzumab govitecan-hziy Submitted by Gilead Sciences, Inc. on 09/07/2021
Fam-trastuzumab deruxtecan-nxki Submitted by AstraZeneca and Daiichi-Sankyo, Inc. on 09/21/2021
Ado-trastuzumab emtansine Submitted by Genentech, Inc. on 09/29/2021
Ribociclib Submitted by Novartis Pharmaceuticals Corporation on 10/11/2021
Abemaciclib Submitted by Eli Lilly and Company on 10/14/2021
Abemaciclib Submitted by Agilent Technologies, Inc. on 10/20/2021
Abemaciclib Submitted by Eli Lilly and Company on 10/28/2021
Docetaxel plus carboplatin Submitted by Guangdong Academy of Medical Sciences on 11/14/2021
bioimpedance spectroscopy Submitted by Cleveland Clinic on 11/20/2021
Adjuvant Olaparib Submitted by AstraZeneca on 12/13/2021
tucatinib_trastuzumab_capecitabine Submitted by The University of Texas MD Anderson Cancer Center on 01/25/2022
tucatinib Submitted by Seagen Inc on 02/03/2022
bioimpedance spectroscopy Submitted by Vanderbilt University School of Nursing on 02/09/2022
olaparib Submitted by AstraZeneca on 03/24/2022
ipilimumab Submitted by Bristol-Myers Squibb Company on 04/11/2022
Fam-trastuzumab deruxtecan-nxki Submitted by AstraZeneca and Daiichi-Sankyo, Inc. on 06/06/2022
ribociclib Submitted by Novartis Pharmaceuticals Corporation on 06/06/2022
Sacituzumab govitecan-hziy Submitted by Gilead Sciences, Inc. on 06/10/2022
eribulin Submitted by Eisai Inc. on 06/11/2022
70-gene assay Submitted by Agendia, Inc. on 06/20/2022
neratinib_fulvestrant_trastuzumab Submitted by Puma Biotechnology on 07/18/2022
SBRT Submitted by Genesis Care/Michigan Healthcare Professionals on 07/22/2022
IMRT Submitted by Genesis Care/Michigan Healthcare Professionals on 07/22/2022
zoladex Submitted by TerSera Therapeutics on 07/22/2022
CGP Submitted by Guardant Health on 07/25/2022
NGS Submitted by Foundation Medicine, Inc. on 07/27/2022
Perjeta and Herceptin Submitted by Genentech, Inc. on 07/29/2022
fam-trastuzumab deruxtecan-nxki Submitted by AstraZeneca and Daiichi-Sankyo, Inc. on 08/08/2022
Sacituzumab govitecan-hziy Submitted by Gilead Sciences, Inc. on 09/12/2022
Ribociclib Submitted by Novartis Pharmaceuticals Corporation on 12/20/2022
Alpelisib Submitted by Novartis Pharmaceuticals Corporation on 12/20/2022
Eribulin Submitted by Eisai Inc. on 01/26/2023
Elacestrant Submitted by Stemline Therapeutics, Inc. on 01/30/2023
Guardant360 CDx Submitted by Guardant Health on 01/30/2023
Abemaciclib Submitted by Eli Lilly and Company on 03/10/2023
Palbociclib Submitted by Pfizer Inc. on 04/07/2023
Pembrolizumab Submitted by Merck & Co., Inc. on 05/01/2023
Olaparib Submitted by AstraZeneca on 05/26/2023
Oncogenic Submitted by Debyani Chakravarty on 05/30/2023
RCB score Submitted by American Joint Committee on Cancer/American College of Surgeons on 07/06/2023
Leuprolide Submitted by Compass Oncology, The US Oncology Network on 07/18/2023
DPYD testing Submitted by Advocates for Universal DPD/DPYD Testing (AUDT) on 07/28/2023
CDx Submitted by Guardant Health on 07/31/2023
ctDNA Submitted by Natera, Inc. on 07/31/2023
EndoPredict Submitted by Myriad Genetic Laboratories, Inc. on 07/31/2023
Locoregional therapies Submitted by Society of Interventional Oncology on 07/31/2023
NGS Submitted by Foundation Medicine, Inc. on 08/02/2023
ipilimimab + nivolumab Submitted by Sylvia Adams and Razelle Kurzrock on 10/16/2023
Capivasertib with Fulvestrant Submitted by Foundation Medicine Inc on 11/16/2023
Capivasertib + fulvestrant Submitted by Astrazeneca on 11/16/2023
Capivasertib + fulvestrant Submitted by Astrazeneca on 11/16/2023
Capivasertib + fulvestrant Submitted by Astrazeneca on 11/16/2023
Capivasertib + fulvestrant Submitted by Astrazeneca on 11/16/2023
Capivasertib + fulvestrant Submitted by Astrazeneca on 11/16/2023
Capivasertib + fulvestrant Submitted by Astrazeneca on 11/16/2023
Capivasertib + fulvestrant Submitted by Astrazeneca on 11/16/2023
PIK3CA/AKT1/PTEN Submitted by Foundation Medicine Inc on 12/15/2023
PIK3CA or AKT1/PTEN Submitted by Foundation Medicine Inc on 12/15/2023
Sacituzumab govitecan-hziy Submitted by Evicore on 01/05/2024
Sacituzumab govitecan-hziy Submitted by Evicore on 01/05/2024
abemaciclib in combination with endocrine therapy Submitted by Eli Lilly and Company on 01/11/2024
Adjuvant Endocrine Therapy-monarchE 5-yrear data outcomes Submitted by Eli Lilly and Company on 01/11/2024
abemaciclib in combination with endocrine therapy Submitted by Eli Lilly and Company on 01/11/2024
Preoperative/Adjuvant Therapy Regimens-monarchE 5-year outcomes Submitted by Eli Lilly and Company on 01/11/2024
Repotrectinib Submitted by BMS on 06/14/2024
ribociclib Submitted by Novartis on 09/17/2024
Ribociclib Submitted by Novartis on 09/17/2024
Ribociclib Submitted by Novartis on 09/17/2024
Ribociclib Submitted by Novartis on 09/17/2024
Ribociclib Submitted by Novartis on 09/17/2024
Ribociclib Submitted by Novartis on 09/17/2024
Ribociclib Submitted by Novartis on 09/17/2024
Ribociclib Submitted by Novartis on 09/17/2024
Ribociclib Submitted by Novartis on 09/17/2024
Inavolisib in combination with Palbociclib and Fulvestrant Submitted by Genentech, Inc. on 10/10/2024
Inavolisib in combination with Palbociclib and Fulvestrant Submitted by Genentech, Inc. on 10/10/2024
Inavolisib in combination with Palbociclib and Fulvestrant Submitted by Genentech, Inc. on 10/10/2024
Inavolisib/ Palbociclib/ Fulvestrant Submitted by Foundation Medicine Inc. on 10/11/2024

Breast Cancer Risk Reduction Panel

riskScore™ Submitted by Myriad Genetic Laboratories, Inc. on 07/06/2020
BBDRisk Dx® MAAA (Multianalyte Assays with Algorithmic Analysis) Submitted by Silbiotech on 07/10/2020
Suggested Updates to CanRisk Tool (BOADICEA) Submitted by Centre for Cancer Genetic Epidemiology on 06/16/2022
geneType model Submitted by Phenogen Sciences, Inc on 03/13/2023
Polygenic Risk Score Submitted by Myriad Genetic Laboratories, Inc. on 04/21/2023
Polygenic Risk Scores (PRS) Submitted by Myriad Genetics on 04/22/2024
Rationale: Polygenic Risk Scores (PRS) Submitted by Myriad Genetics on 04/22/2024

Breast Cancer Screening and Diagnosis Panel

Polygenic Risk Score Submitted by Myriad Genetic Laboratories, Inc. on 10/03/2022
Dense breasts Submitted by Operation Breast Denisty on 03/06/2023

Cancer in People with HIV/Kaposi Sarcoma Panel

Pomalidomide Submitted by Bristol-Myers Squibb Company on 05/19/2020
Galleri Submitted by Grail, Inc. on 08/02/2021
Multi-cancer early detection (MCED) testing Submitted by GRAIL on 06/11/2024
Multi-cancer early detection (MCED) testing Submitted by GRAIL on 06/11/2024
Multi-cancer early detection (MCED) testing Submitted by GRAIL on 06/11/2024
Multi-cancer early detection (MCED) testing Submitted by GRAIL on 06/11/2024
Multi-cancer early detection (MCED) testing Submitted by GRAIL on 06/11/2024
Repotrectinib Submitted by BMS on 06/14/2024
Repotrectinib Submitted by BMS on 06/14/2024

Cancer-Associated Venous Thromboembolic Disease Panel

Andexanet alfa Submitted by Bristol-Myers Squibb Company on 06/25/2020
Acute DVT Submitted by Society of Interventional Oncology on 10/27/2020

Central Nervous System Cancers Panel

Tucatinib Submitted by Seattle Genetics, Inc. on 05/29/2020
Aminolevulinic acid hydrochloride Submitted by NX Development Corp on 06/02/2020
Pembrolizumab Submitted by Merck & Co., Inc. on 06/17/2020
Nivolumab + Ipilimumab Submitted by Bristol-Myers Squibb Company on 06/23/2020
Tumor Mutational Burden (TMB) Submitted by Foundation Medicine, Inc. on 06/24/2020
Laser Interstitial Thermal Therapy (LITT) Submitted by Washington University School of Medicine; Department of Neurological Surgery on 08/28/2020
Tumor Mutational Burden (TMB) Submitted by Foundation Medicine, Inc. on 09/18/2020
Capmatinib Submitted by Novartis Pharmaceuticals Corporation on 12/11/2020
Nivolumab + Ipilimumab Submitted by Bristol-Myers Squibb Company on 06/04/2021
Selpercatinib Submitted by Eli Lilly and Company on 06/16/2021
Belzutifan Submitted by Merck & Co., Inc. on 08/19/2021
Nivolumab + Ipilimumab Submitted by Bristol-Myers Squibb Company on 09/09/2021
Tepotinib Submitted by EMD Serono on 09/13/2021
Fam-trastuzumab deruxtecan-nxki Submitted by Daiichi-Sankyo, Inc. on 09/22/2021
Request the addition of tucatinib + trastuzumab + capecitabine in HER2 positive breast cancer and leptomeningeal metastasis. Submitted by The University of Texas MD Anderson Cancer Center on 01/25/2022
Consider the inclusion of tucatinib in combination with trastuzumab and capecitabine for patients with leptomeningeal metastases. Submitted by Seagen, Inc. on 02/03/2022
Request to include nivolumab in combination with ipilimumab for patients with TMB-H (tTMB-H) CNS Submitted by Bristol-Myers Squibb Company on 04/11/2022
Request the inclusion of autologous tumor lysate-loaded dendritic cell vaccination as adjuvant treatment option Submitted by Harting Communications LLC on 05/27/2022
Consider recommendations for radiation therapy for brain metastases and glioma. Submitted by American Society for Radiation Oncology on 09/09/2022
Request the inclusion of ivosidenib as a treatment option for CNS Submitted by Servier Pharmaceuticals LLC on 09/13/2022
Request the inclusion of selpercatinib for RET fusion-positive CNS and RET gene fusion testing in the guidelines. Submitted by Eli Lilly and Company on 09/21/2022
Request the inclusion of tepotinib for MET exon 14 skipping mutation NSCLC with brain or leptomeningeal metastases. Submitted by EMD Serono on 09/28/2022
Request the addition of nivolumab + ipilimumab + 2 cycles of chemotherapy. Submitted by Bristol-Myers Squibb Company on 11/11/2022
Sotorasib Submitted by Amgen Inc. on 06/04/2023
Nivolumab in combination with ipilimumab Submitted by Bristol-Myers Squibb Company on 06/06/2023
Intrathecal nivolumab Submitted by The University of Texas MD Anderson Cancer Center on 06/25/2023
Adagrasib Submitted by Mirati Therapeutics, Inc. on 06/28/2023
Add a section for brachytherapy implant Submitted by GT Medical Technologies, Inc. on 08/03/2023
Olutasidenib Submitted by Rigel Pharmaceuticals, Inc.  on 09/08/2023
Repotrectinib Submitted by BMS on 06/13/2024
Repotrectinib Submitted by BMS on 06/13/2024
Repotrectinib Submitted by BMS on 06/13/2024
Repotrectinib Submitted by BMS on 06/13/2024
Vorasidenib Submitted by Servier Pharmaceuticals on 07/03/2024
Vorasidenib Submitted by Servier Pharmaceuticals on 07/03/2024
Vorasidenib Submitted by Servier Pharmaceuticals on 07/03/2024
Vorasidenib Submitted by Servier Pharmaceuticals on 07/03/2024
Vorasidenib Submitted by Servier Pharmaceuticals on 08/06/2024
Vorasidenib Submitted by Servier Pharmaceuticals on 08/06/2024

Cervical/Uterine Cancers Panel

Pembrolizumab for Cervical Cancer Submitted by Merck & Co., Inc. on 06/17/2020
Pembrolizumab for Uterine Neoplasms Submitted by Merck & Co., Inc. on 06/17/2020
Pembrolizumab for Vulvar Cancer Submitted by Merck & Co., Inc. on 06/17/2020
Pembrolizumab and TMB testing for Cervical Cancer Submitted by Foundation Medicine, Inc. on 06/22/2020
Pembrolizumab and TMB testing for Vulvar Cancer Submitted by Foundation Medicine, Inc. on 06/22/2020
Pembrolizumab and TMB testing for Uterine Neoplasms Submitted by Foundation Medicine, Inc. on 06/30/2020
Avelumab Submitted by EMD Serono on 08/11/2020
Oral selixinor for Endometrial Carcinoma Submitted by Karyopharm Therapeutics on 01/21/2021
Lenvatinib in combination with Pembrolizumab Submitted by Eisai Inc. on 02/11/2021
Lenvatinib and pembrolilzumab for Uterine Neoplasms Submitted by Eisai Inc. on 02/11/2021
Pembrolizumab in combination with Lenvatinib Submitted by Merck & Co., Inc. on 03/19/2021
Pembrolizumab and Lenvatinib for Uterine Neoplasms Submitted by Merck & Co., Inc. on 03/19/2021
Dostarlimab-gxly Submitted by GlaxoSmithKline on 04/21/2021
Dostarlimab-gxly (Uterine Neoplasms) Submitted by GlaxoSmithKline on 04/22/2021
Dostarlimab-gxly for Uterine Neoplasms Submitted by GlaxoSmithKline on 04/28/2021
Cabozantinib Submitted by Exelixis Inc. on 05/05/2021
Cabozantinib for Uterine Neoplasms Submitted by Exelixis Inc. on 05/05/2021
TMB Testing for Cervical Cancer Submitted by Illumina Inc. on 05/13/2021
Comprehensive genomic profiling for Uterine Neoplasms Submitted by Illumina Inc. on 05/13/2021
Comprehensive genomic profiling for Vulvar Cancer Submitted by Foundation Medicine, Inc. on 05/14/2021
Tisotumab vedotin-tftv for Cervical Cancer Submitted by Seagen Inc on 05/14/2021
Comprehensive genomic profiling for Uterine Neoplasms Submitted by Foundation Medicine, Inc. on 05/14/2021
Genetic Risk Assessment for Uterine Neoplasms Submitted by Ambry Genetics, GeneDx, Illumina Inc., Myriad Genetic Laboratories, Inc. and Quest Diagnostics on 05/21/2021
Lenvatinib in combination with Pembrolizumab Submitted by Eisai Inc. on 06/17/2021
Pembrolizumab Submitted by Merck & Co., Inc. on 06/18/2021
Pembrolizumab in combination with Lenvatinib Submitted by Merck & Co., Inc. on 07/22/2021
Pembrolizumab (Uterine) Submitted by Merck & Co., Inc. on 09/20/2021
Fam-trastuzumab deruxtecan-nxki (Uterine) Submitted by AstraZeneca and Daiichi-Sankyo, Inc. on 09/24/2021
Pembrolizumab in combination with chemotherapy, with or without bevacizumab for Cervical Cancer Submitted by Merck & Co., Inc. on 10/14/2021
Dostarlimab-gxly (Uterine) Submitted by GlaxoSmithKline on 10/18/2021
Lenvatinib in combination with pembrolizumab (Uterine) Submitted by Eisai Inc. on 11/03/2021
Cemiplimab Submitted by Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme on 02/10/2022
Adjuvant Therapy in Uterine Cancer Stage I and II Submitted by Assam Cancer Care Foundation on 03/16/2022
Pembrolizumab (Uterine) Submitted by Merck & Co., Inc. on 03/23/2022
Pembrolizumab in combination with lenvatinib (Uterine) Submitted by Merck & Co., Inc. on 03/24/2022
Nivolumab with Ipilimumab Submitted by Bristol-Myers Squibb Company on 04/11/2022
Nivolumab with Ipilimumab (Uterine) Submitted by Bristol-Myers Squibb Company on 04/11/2022
ASTRO Guideline reference Submitted by American Society for Radiation Oncology on 04/26/2022
Pembrolizumab Submitted by Merck & Co., Inc. on 05/11/2022
Comprehensive Genomic Profiling (Uterine) Submitted by Foundation Medicine, Inc. on 05/19/2022
Tisotumab vedotin in combination with pembrolizumab Submitted by Seagen Inc on 05/27/2022
Dostarlimab-glxy (Uterine) Submitted by GlaxoSmithKline on 06/08/2022
Selpercatinib for RET fusion-positive tumors Submitted by Eli Lilly and Company on 09/21/2022
Albumin-bound sirolimus (Uterine Sarcoma) Submitted by Aadi Bioscience on 11/10/2022
Dostarlimab-gxly for dMMR/MSI-H tumors (Uterine) Submitted by GlaxoSmithKline on 03/27/2023
Dostarlimab-gxly/carboplatin/paclitaxel (Uterine) Submitted by GlaxoSmithKline on 03/27/2023
Pembrolizumab in combination with carboplatin and paclitaxel (Uterine) Submitted by Merck & Co., Inc. on 04/11/2023
Retifanlimab-dlwr Submitted by Incyte Corporation on 04/18/2023
RT recommendations (Cervical Cancer) Submitted by American Society for Radiation Oncology on 05/18/2023
RT recommendations (Uterine Neoplasms) Submitted by American Society for Radiation Oncology on 05/18/2023
Cemiplimab Submitted by Regeneron Pharmaceuticals, Inc. on 05/19/2023
Footnote (Uterine Sarcoma) Submitted by Memorial Sloan Kettering Cancer Center on 05/30/2023
NGS Submitted by Illumina Inc. on 06/01/2023
Fam-trastuzumab deruxtecan-nxki for HER2-positive tumors (IHC 3+ or 2+) Submitted by AstraZeneca and Daiichi-Sankyo, Inc. on 06/05/2023
Fam-trastuzumab deruxtecan-nxki (Endometrial) Submitted by AstraZeneca and Daiichi-Sankyo, Inc. on 06/05/2023
Sacituzumab govitecan-hziy (Endometrial) Submitted by Gilead Sciences, Inc. on 06/21/2023
Adagrasib for KRAS G12C (Uterine Neoplasms) Submitted by Mirati Therapeutics, Inc. on 08/11/2023
Albumin-bound sirolimus (Uterine Sarcoma) Submitted by Aadi Bioscience on 09/12/2023
Carboplatin + paclitaxel + durvalumab +/- olaparib (Uterine Neoplasms) Submitted by AstraZeneca on 10/20/2023
Selinexor Submitted by Rigshospitalet on 11/17/2023
Selinexor Submitted by Rigshospitalet on 11/17/2023
Dostarlimab-gxly Submitted by GSK on 12/08/2023
Pembrolizumab Submitted by Merck & Co., Inc. on 01/17/2024
Carboplatin + Paclitaxel + Durvalumab Submitted by AstraZeneca on 03/26/2024
Carboplatin/Paclitaxel/Durvalumab Submitted by AstraZeneca on 03/26/2024

Chronic Myeloid Leukemia Panel

Ponatinib Submitted by Takeda Oncology on 10/21/2020
Asciminib Submitted by Novartis Pharmaceuticals Corporation on 10/20/2021
Asciminib Submitted by Novartis Pharmaceuticals Corporation on 10/29/2021
Ponatinib Submitted by Takeda Oncology on 11/15/2021
Ponatinib Submitted by Takeda Oncology on 04/08/2022
Dasatinib Submitted by Bristol-Myers Squibb Company on 05/23/2023
Asciminib Submitted by Novartis on 06/13/2024
Asciminib Submitted by Novartis on 06/13/2024
Asciminib Submitted by Novartis on 06/13/2024
Asciminib Submitted by Novartis on 06/13/2024
Asciminib Submitted by Novartis on 10/29/2024
Asciminib Submitted by Novartis on 10/29/2024
Asciminib Submitted by Novartis on 10/29/2024
Asciminib Submitted by Novartis on 10/29/2024

CLL/SLL/Hairy Cell Leukemia Panel

Acalabrutinib Submitted by AstraZeneca on 05/23/2020
Venetoclax + Obinutuzumab Submitted by AbbVie, Inc. on 06/02/2020
Zanubrutinib Submitted by BeiGene, Ltd. on 08/03/2020
Venetoclax + Obinutuzumab Submitted by AbbVie, Inc. on 09/11/2020
clonoSEQ Submitted by Adaptive Biotechnologies on 09/30/2020
Rasburicase Submitted by Sanofi on 10/12/2020
Ibrutinib Submitted by Janssen Biotech, Inc. and Pharmacyclics, LLC on 12/06/2020
Venetoclax Submitted by AbbVie, Inc. and Genentech, Inc. on 01/11/2021
MRD Submitted by Adaptive Biotechnologies on 05/14/2021
Vemurafenib + rituximab Submitted by Genentech, Inc. on 05/21/2021
Zanubrutinib Submitted by BeiGene, Ltd. on 12/23/2021
Zanubrutinib Submitted by BeiGene, Ltd. on 12/23/2021
Ibrutinib Submitted by AbbVie, Inc., Janssen Biotech, Inc. and Pharmacyclics, LLC on 05/19/2022
Acalabrutinib Submitted by AstraZeneca on 05/27/2022
MRD testing Submitted by Adaptive Biotechnologies on 05/27/2022
Acalabrutinib Submitted by AstraZeneca on 06/09/2022
Zanubrutinib Submitted by BeiGene, Ltd. on 07/26/2022
Venetoclax + Obinutuzumab Submitted by AbbVie, Inc. and Genentech, Inc. on 08/30/2022
Acalabrutinib Submitted by AstraZeneca on 12/05/2022
Zanubrutinib Submitted by BeiGene, Ltd. on 12/13/2022
Ibrutinib + Venetoclax Submitted by AbbVie, Inc. and Pharmacyclics, LLC on 12/19/2022
Ibrutinib Submitted by AbbVie, Inc. and Pharmacyclics, LLC on 12/20/2022
Ibrutinib Submitted by AbbVie, Inc. and Pharmacyclics, LLC on 12/20/2022
Zanubrutinib Submitted by BeiGene, Ltd. on 01/19/2023
Cetirizine Submitted by TerSera Therapeutics on 03/27/2023
BTK inhibitors Submitted by AstraZeneca on 05/25/2023
Ibrutinib + Venetoclax Submitted by AbbVie, Inc. and Pharmacyclics, LLC on 05/29/2023
Ibrutinib + Venetoclax Submitted by AbbVie, Inc. and Janssen Biotech, Inc. on 01/24/2024
Lisocabtagene Maraleucel Submitted by BMS on 01/26/2024
Tislelizumab Submitted by BeiGene, Ltd. on 03/14/2024
Lisocabtagene Maraleucel Submitted by BMS on 03/15/2024
Lisocabtagene Maraleucel Submitted by BMS on 03/18/2024
Lisocabtagene Maraleucel Submitted by BMS on 03/18/2024
Lisocabtagene Maraleucel Submitted by BMS on 03/18/2024
Ibrutinib Submitted by AbbVie, Inc. and Janssen Biotech, Inc. on 05/09/2024
Ibrutinib Submitted by AbbVie, Inc. and Janssen Biotech, Inc. on 05/09/2024
Ibrutinib Submitted by AbbVie, Inc. and Janssen Biotech, Inc. on 05/24/2024
Ibrutinib + Venetoclax Submitted by AbbVie, Inc. and Janssen Biotech, Inc. on 05/24/2024
Lisocabtagene Maraleucel Submitted by Bristol-Myers Squibb Company on 06/03/2024
Cetirizine Submitted by TerSera Therapeutics on 10/03/2024

Colon/Rectal/Anal Cancers Panel

Pembrolizumab for Rectal Cancer Submitted by Merck & Co., Inc. on 06/01/2020
Pembrolizumab for Colon Cancer Submitted by Merck & Co., Inc. on 06/01/2020
Nivolumab + Ipilimumab Submitted by Bristol-Myers Squibb Company on 06/01/2020
Trifluridine and Tipiracil Submitted by Taiho Oncology, Inc. on 06/10/2020
Pembrolizumab for Small Bowel Adenocarcinoma Submitted by Merck & Co., Inc. on 06/17/2020
Tumor Mutational Burden (TMB) for Colon Cancer Submitted by Foundation Medicine, Inc. on 06/22/2020
Tumor Mutational Burden (TMB) for Rectal Cancer Submitted by Foundation Medicine, Inc. on 06/22/2020
Immunoscore assay Submitted by HalioDx on 06/25/2020
Pembrolizumab for Colon Cancer Submitted by Merck & Co., Inc. on 06/30/2020
Pembrolizumab for Rectal Cancer Submitted by Merck & Co., Inc. on 06/30/2020
Fam-trastuzumab deruxtecan-nxki Submitted by AstraZeneca and Daiichi-Sankyo, Inc. on 07/09/2020
Post-surgical tumor-informed ctDNA for Colon Cancer Submitted by Natera, Inc. on 07/13/2020
Tumor-informed ctDNA for Colon Cancer Submitted by Natera, Inc. on 07/13/2020
Post-surgical tumor-informed ctDNA for Rectal Cancer Submitted by Natera, Inc. on 07/13/2020
Tumor-informed ctDNA for Rectal Cancer Submitted by Natera, Inc. on 07/13/2020
yttrium-90 Submitted by Society of Interventional Oncology on 07/14/2020
Next-generation sequencing (NGS) Submitted by Guardant Health on 07/20/2020
Circulating Tumor DNA (ctDNA) Submitted by Colorectal Cancer Alliance on 08/10/2020
Pralsetinib Submitted by Blueprint Medicines on 09/08/2020
Tumor Mutational Burden (TMB) for Small Bowel Adenocarcinoma Submitted by Foundation Medicine, Inc. on 09/16/2020
Tumor Mutational Burden (TMB) for Colon Cancer Submitted by Foundation Medicine, Inc. on 09/18/2020
Tumor Mutational Burden (TMB) for Rectal Cancer Submitted by Foundation Medicine, Inc. on 09/18/2020
Lenvatinib + Pembrolizumab Submitted by Eisai Inc. on 10/04/2020
Pembrolizumab for Colon Cancer Submitted by Merck & Co., Inc. on 12/04/2020
Pembrolizumab for Rectal Cancer Submitted by Merck & Co., Inc. on 12/04/2020
Trifluridine and Tipiracil Submitted by Taiho Oncology, Inc. on 02/16/2021
Panitumumab Submitted by Amgen Inc. on 06/24/2021
CGP for Colon Cancer Submitted by Foundation Medicine, Inc. on 06/29/2021
CGP for Rectal Cancer Submitted by Foundation Medicine, Inc. on 06/29/2021
ctDNA for Colon Cancer Submitted by Clinical Genomics Pathology, Inc on 06/30/2021
ctDNA for Rectal Cancer Submitted by Clinical Genomics Pathology, Inc on 06/30/2021
Encorafenib + Cetuximab Submitted by Pfizer Inc. on 07/01/2021
CGP for Colon Cancer Submitted by Guardant Health on 07/02/2021
CGP for Rectal Cancer Submitted by Guardant Health on 07/02/2021
Dostarlimab-gxly for Colon Cancer Submitted by GlaxoSmithKline on 08/17/2021
Dostarlimab-gxly for Rectal Cancer Submitted by GlaxoSmithKline on 08/17/2021
Dostarlimab-gxly for Small Bowel Adenocarcinoma Submitted by GlaxoSmithKline on 08/17/2021
Contrast-Enhanced Ultrasound for Colon Cancer Submitted by International Contrast Ultrasound Society on 10/07/2021
Sotorasib for Colon/Rectal Cancers Submitted by Amgen Inc. on 12/15/2021
Sotorasib for Colon/Rectal Cancers Submitted by Amgen Inc. on 12/15/2021
CEA level for Rectal Cancer Submitted by The Sixth Affiliated Hospital, Sun Yat-sen University on 03/10/2022
Lateral lymph nodes dissection for Rectal Cancer Submitted by The Sixth Affiliated Hospital, Sun Yat-sen University on 03/10/2022
Nivolumab + ipilimumab for Anal Carcinoma Submitted by Bristol-Myers Squibb Company on 04/11/2022
Nivolumab + ipilimumab for Small Bowel Adenocarcinoma Submitted by Bristol-Myers Squibb Company on 04/11/2022
Nivolumab + ipilimumab for Colon Cancer Submitted by Bristol-Myers Squibb Company on 04/11/2022
Nivolumab + ipilimumab for Rectal Cancer Submitted by Bristol-Myers Squibb Company on 04/11/2022
ASTRO Guideline for Rectal Cancer Submitted by American Society for Radiation Oncology on 04/26/2022
Surveillance for Anal Carcinoma Submitted by Patient on 05/09/2022
Pembrolizumab for Colon Cancer Submitted by Merck & Co., Inc. on 05/12/2022
Pembrolizumab for Rectal Cancer Submitted by Merck & Co., Inc. on 05/12/2022
Metastasis to peritoneum only for Rectal Cancer Submitted by NSCB Cancer Hospital on 05/31/2022
Dostarlimab-gxly for Rectal Cancer Submitted by GlaxoSmithKline on 06/24/2022
ctDNA testing for Colon/Rectal Cancers Submitted by Colorectal Cancer Alliance on 07/08/2022
ctDNA testing for Colon/Rectal Cancers Submitted by Fight Colorectal Cancer on 07/18/2022
ctDNA for Rectal Cancer Submitted by Natera, Inc. on 07/19/2022
ctDNA for Colon Cancer Submitted by Natera, Inc. on 07/19/2022
ctDNA testing for Colon/Rectal Cancers Submitted by COLONTOWN on 07/21/2022
ctDNA testing for Colon/Rectal Cancers Submitted by Colon Cancer Coalition on 07/25/2022
FOLFOX + panitumumab for Colon/Rectal Cancers Submitted by Amgen Inc. on 07/25/2022
Trifluridine/tipiracil plus bevacizumab Submitted by Taiho Oncology, Inc. on 07/27/2022
DPYD variant testing for Anal Carcinoma Submitted by Invitae on 08/01/2022
DPYD variant testing for Colon/Rectal Cancers Submitted by Invitae on 08/01/2022
CGP for Colon Cancer Submitted by Foundation Medicine, Inc. on 08/02/2022
CGP for Rectal Cancer Submitted by Foundation Medicine, Inc. on 08/02/2022
Sotorasib + panitumumab for Colon/Rectal Cancers Submitted by Amgen Inc. on 09/15/2022
Selpercatinib for Colon/Rectal Cancer Submitted by Eli Lilly and Company on 09/21/2022
Selpercatinib for Small Bowel Adenocarcinoma Submitted by Eli Lilly and Company on 09/21/2022
Adagrasib monotherapy and adagrasib + cetuximab for Rectal Cancer Submitted by Mirati Therapeutics, Inc. on 12/12/2022
Adagrasib monotherapy and adagrasib + cetuximab for Colon Cancer Submitted by Mirati Therapeutics, Inc. on 12/12/2022
Tucatinib + trastuzumab for Rectal Cancer Submitted by Seagen Inc on 01/20/2023
Tucatinib + trastuzumab for Colon Cancer Submitted by Seagen Inc on 01/20/2023
Trifluridine + tipiracil + bevacizumab for Colon/Rectal Cancers Submitted by Taiho Oncology, Inc. on 01/21/2023
Retifanlimab-dlwr for Anal Carcinoma Submitted by Incyte Corporation on 04/18/2023
Trifluridine/tipiracil plus bevacizumab for Colon/Rectal Cancer Submitted by Taiho Oncology, Inc. on 05/03/2023
Dostarlimab-gxly for Rectal Cancer Submitted by GlaxoSmithKline on 05/03/2023
Fam-trastuzumab deruxtecan-nxki for Rectal Cancer Submitted by Daiichi-Sankyo, Inc. on 06/21/2023
Fam-trastuzumab deruxtecan-nxki for Colon Cancer Submitted by Daiichi-Sankyo, Inc. on 06/21/2023
FOLFOX + panitumumab for Colon/Rectal Cancers Submitted by Amgen Inc. on 06/22/2023
ctDNA for Rectal Cancer Submitted by Natera, Inc. on 06/22/2023
ctDNA for Colon Cancer Submitted by Natera, Inc. on 06/22/2023
Ziv-aflibercept for Colon/Rectal Cancers Submitted by Sanofi on 06/30/2023
Ziv-aflibercept for Colon/Rectal Cancers Submitted by Sanofi on 06/30/2023
Interventional Oncology for Colon/Rectal Cancers Submitted by Society of Interventional Oncology on 07/10/2023
Transanal full thickness local excision for Rectal Cancer Submitted by Ascension St. John Hospital on 07/14/2023
Quantitative multiparametric MRI for Colon Cancer Submitted by Perspectum Ltd on 07/17/2023
Radiation Oncology for Rectal Cancer Submitted by American Society for Radiation Oncology on 07/20/2023
Immunoscore for Colon Cancer Submitted by National Institute of Health and Medical Research, France on 07/20/2023
Tucatinib plus trastuzumab for Colon Cancer Submitted by Seagen Inc on 07/27/2023
Tucatinib plus trastuzumab for Rectal Cancer Submitted by Seagen Inc on 07/27/2023
CGP for Rectal Cancer Submitted by Foundation Medicine, Inc. on 07/27/2023
CGP for Colon Cancer Submitted by Foundation Medicine, Inc. on 07/27/2023
Immunoscore for Rectal Cancer Submitted by National Institute of Health and Medical Research, France on 07/28/2023
CDx for Colon Cancer Submitted by Guardant Health on 07/29/2023
CDx for Rectal Cancer Submitted by Guardant Health on 07/31/2023
Adagrasib monotherapy and adagrasib + cetuximab for Colon/Rectal Cancers Submitted by Colorectal Cancer Alliance on 08/04/2023
Avelumab for Colon/Rectal Cancers Submitted by EMD Serono on 08/21/2023
Fruquintinib Submitted by Takeda Oncology on 11/09/2023
Fruquintinib Submitted by Takeda Oncology on 11/09/2023
Fruquintinib Submitted by Takeda Oncology on 11/09/2023
Fruquintinib Submitted by Takeda Oncology on 11/09/2023
Repotrectinib Submitted by BMS on 06/14/2024
Repotrectinib Submitted by BMS on 06/14/2024
Repotrectinib Submitted by BMS on 06/14/2024
Repotrectinib Submitted by BMS on 06/14/2024
Repotrectinib Submitted by BMS on 06/14/2024

Colorectal Cancer Screening Panel

Epi proColon Submitted by Epigenomics Inc. on 09/28/2020
FIT-DNA-based testing Submitted by Exact Sciences Inc. on 10/13/2020
mt-s DNA Submitted by Exact Sciences Inc. on 03/08/2021
mt-s DNA Test Submitted by on 10/06/2021
Galleri Test Submitted by Grail, Inc. on 10/09/2023

Distress Management Panel

Distress Thermometer tool Submitted by Navigating Cancer on 12/18/2023
Utility difficulties Submitted by The US Oncology Network on 01/22/2024

Esophageal/Gastric Cancers Panel

Fam-trastuzumab deruxtecan-nxki Submitted by Daiichi-Sankyo, Inc. on 06/04/2020
Fam-trastuzumab deruxtecan-nxki (Esophageal and Gastric Cancers) Submitted by AstraZeneca and Daiichi-Sankyo, Inc. on 06/04/2020
Nivolumab for Esophageal squamous cell carcinoma Submitted by Bristol-Myers Squibb Company on 06/11/2020
Pembrolizumab for TMB-H for Esophageal Cancer Submitted by Merck & Co., Inc. on 06/17/2020
Pembrolizumab for TMB for Gastric Cancer Submitted by Merck & Co., Inc. on 06/17/2020
Tumor mutational burden (TMB) testing for Esophageal Cancer Submitted by Foundation Medicine, Inc. on 06/22/2020
Tumor mutational burden (TMB) testing for Gastric Cancer Submitted by Foundation Medicine, Inc. on 06/22/2020
Comprehensive genomic profiling for Esophageal Cancer Submitted by Foundation Medicine, Inc. on 08/26/2020
Tumor mutational burden (TMB) testing for Gastric Cancer Submitted by Foundation Medicine, Inc. on 08/26/2020
Plasma-based comprehensive genomic profiling Submitted by Guardant Health on 08/26/2020
Pembrolizumab with chemotherapy for Esophageal Cancer Submitted by Merck & Co., Inc. on 09/21/2020
Nivolumab for Esophageal Cancer Submitted by Bristol-Myers Squibb Company on 09/23/2020
Nivolumab for Gastric Cancer Submitted by Bristol-Myers Squibb Company on 09/23/2020
Pembrolizumab for Esophageal Cancer Submitted by Merck & Co., Inc. on 11/04/2020
Fam-trastuzumab deruxtecan-nxki (Esophageal and Gastric Cancers) Submitted by AstraZeneca and Daiichi-Sankyo, Inc. on 01/21/2021
Pembrolizumab in combination with oxaliplatin and fluoropyrimidine based chemotherapy (Esophageal) Submitted by Merck & Co., Inc. on 03/23/2021
Pembrolizumab in combination with oxaliplatin and fluoropyrimidine based chemotherapy (Esophageal) Submitted by Merck & Co., Inc. on 03/31/2021
Nivolumab in combination with oxaliplatin and fluorouracil or capecitabine (Esophageal) Submitted by Bristol-Myers Squibb Company on 04/16/2021
Nivolumab in combination with oxaliplatin and fluorouracil or capecitabine (Gastric) Submitted by Bristol-Myers Squibb Company on 04/16/2021
Pembrolizumab, in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy (Gastric) Submitted by Merck & Co., Inc. on 05/06/2021
Pembrolizumab (Gastric) Submitted by Merck & Co., Inc. on 05/18/2021
Pembrolizumab, in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy (Gastric) Submitted by Merck & Co., Inc. on 06/04/2021
Nivolumab in combination with chemotherapy (Esophageal) Submitted by Bristol-Myers Squibb Company on 06/07/2021
Nivolumab and Ipilimumab Submitted by Bristol-Myers Squibb Company on 06/07/2021
Pembrolizumab (Gastric) Submitted by Merck & Co., Inc. on 06/18/2021
Trifluridine and tipiracil (Esophageal and Gastric) Submitted by Taiho Oncology, Inc. on 07/26/2021
Radiation dosing and techniques (Esophageal) Submitted by American Society for Radiation Oncology on 07/27/2021
Plasma-based comprehensive genomic profiling Submitted by Guardant Health on 08/08/2021
Comprehensive genomic profiling (Esophageal) Submitted by Foundation Medicine, Inc. on 08/10/2021
Comprehensive genomic profiling (Gastric) Submitted by Foundation Medicine, Inc. on 08/10/2021
Dostarlimab-gxly Submitted by GlaxoSmithKline on 08/17/2021
Genetic Risk Assessment (Gastric) Submitted by Ambry Genetics, GeneDx Inc, Myriad Genetic Laboratories Inc, Quest Diagnostics Laboratories and AliveAndKickn on 08/17/2021
Methylation-based blood test (Esophageal and Gastric) Submitted by Grail, Inc. on 08/22/2021
Pembrolizumab in combination with chemotherapy Submitted by Merck & Co., Inc. on 08/30/2021
Nivolumab in combination with chemotherapy Submitted by Bristol-Myers Squibb Company on 09/24/2021
Nivolumab in combination with chemotherapy Submitted by Bristol-Myers Squibb Company on 01/26/2022
Nivolumab in combination with ipilimumab for tTMB-H tumors Submitted by Bristol-Myers Squibb Company on 04/11/2022
Nivolumab with Ipilimumab for (tTMB-H) (Gastric) Submitted by Bristol-Myers Squibb Company on 04/11/2022
Tislelizumab (Esophageal) Submitted by Novartis Pharmaceuticals Corporation on 05/26/2022
Nivolumab and Ipilimumab Submitted by Bristol-Myers Squibb Company on 05/31/2022
Spatialomics risk stratification (Esophageal) Submitted by Castle Biosciences on 07/26/2022
Nivolumab + Chemotherapy and Nivolumab and Ipilimumab Submitted by Bristol-Myers Squibb Company on 08/01/2022
Genetic risk assessment (Gastric) Submitted by AliveAndKickn, Ambry Genetics, FORCE, GeneDx, Illumina Inc., Myriad Genetic Laboratories, Inc. and Quest Diagnostics on 08/01/2022
Selpercatinib (Esophageal) Submitted by Eli Lilly and Company on 09/21/2022
Selpercatinib (Gastric) Submitted by Eli Lilly and Company on 09/21/2022
Nivolumab plus ipilimumab (Esophageal) Submitted by Bristol-Myers Squibb Company on 01/20/2023
Pembrolizumab in combination with fluoropyrimidine- and platinum-based chemotherapy (Gastric) Submitted by Merck & Co., Inc. on 02/17/2023
Pembrolizumab (Esophageal) Submitted by Merck & Co., Inc. on 03/30/2023
Nivolumab in combination with chemotherapy (Esophageal/Gastric) Submitted by Bristol-Myers Squibb Company on 06/06/2023
PET-directed therapy (Esophageal) Submitted by Icahn School of Medicine at Mount Sinai on 06/25/2023
Gastric Cancer Risk Assessment Submitted by AliveAndKickn, Ambry Genetics, Illumina Inc., Myriad Genetic Laboratories, Inc., Quest Diagnostics and Volpara Health on 06/26/2023
Wide-area Transepithelial Sampling with Three-dimensional Analysis (Esophageal) Submitted by CDx Diagnostics on 07/13/2023
Circulating tumor DNA (Esophageal) Submitted by Natera, Inc. on 07/28/2023
Circulating tumor DNA (Gastric) Submitted by Natera, Inc. on 07/28/2023
Comprehensive genomic profiling/Next-generation sequencing (Esophageal) Submitted by Foundation Medicine, Inc. on 07/31/2023
Comprehensive genomic profiling/Next-generation sequencing (Gastric) Submitted by Foundation Medicine, Inc. on 07/31/2023
Pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy (Gastric) Submitted by Merck & Co., Inc. on 10/20/2023
Pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy (Esophageal) Submitted by Merck & Co., Inc. on 10/20/2023
Nivolumab plus ipilimumab for MSI-H/dMMR tumors (Esophageal/Gastric) Submitted by Bristol-Myers Squibb Company on 10/23/2023
Pembrolizumab W/ Trastuzumab, Fluoropyrimidine- and Platinum-Containing Chemotherapy (Gastric) Submitted by Merck & Co., Inc. on 11/21/2023
Pembrolizumab W/ Trastuzumab, Fluoropyrimidine- and Platinum-Containing Chemotherapy Submitted by Merck & Co., Inc. on 11/21/2023
Pembrolizumab w/ Fluoropyrimidine- and Platinum-Containing Chemotherapy (Gastric) Submitted by Merck & Co., Inc. on 11/21/2023
Pembrolizumab w/ Oxaliplatin- and Fluoropyrimidine-based Chemotherapy (Esophageal) Submitted by Merck & Co., Inc. on 11/21/2023
tislelizumab Submitted by BeiGene USA on 03/14/2024
Pembrolizumab (Gastric) Submitted by Merck & Co., Inc. on 03/30/2024
Repotrectinib Submitted by BMS on 06/14/2024
Repotrectinib Submitted by BMS on 06/14/2024
Repotrectinib Submitted by BMS on 06/14/2024
Repotrectinib Submitted by BMS on 06/14/2024
Repotrectinib Submitted by BMS on 06/14/2024

Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic Panel

Polygenic Risk Scores Submitted by Myriad Genetic Laboratories, Inc. on 03/16/2021
Polygenic Risk Scores Submitted by Bright Pink on 03/17/2021
Genetic Testing Criteria Submitted by Ambry Genetics, GeneDx, Illumina Inc., Myriad Genetic Laboratories, Inc. and Quest Diagnostics on 03/17/2021
Genetic testing Submitted by AliveAndKickn, Ambry Genetics, GenPath Oncology, Illumina Inc., Myriad Genetic Laboratories, Inc. and Quest Diagnostics on 02/22/2022
Polygenic risk scores Submitted by Myriad Genetic Laboratories, Inc. on 03/28/2022
Genetic testing Submitted by Invitae on 03/31/2022
Genetic testing Criteria Submitted by Ambry Genetics, GeneDx, Illumina Inc., Myriad Genetic Laboratories, Inc. and Quest Diagnostics on 03/02/2023
Polygenic risk scores Submitted by Myriad Genetic Laboratories, Inc. on 03/07/2023
Genetic Testing Criteria Submitted by Invitae on 03/13/2023
ODX RS Submitted by AstraZeneca on 05/19/2023
Testing Age Submitted by AstraZeneca on 08/03/2023

Genetic/Familial High-Risk Assessment: Colorectal Panel

CRC Modifications Submitted by Myriad Genetic Laboratories, Inc. on 11/05/2020
Microsatellite Instability assays Submitted by Promega Corporation on 10/27/2021
Lynch syndrome and Polyposis Submitted by AliveAndKickn, Ambry Genetics, FORCE, GenPath Oncology, Illumina Inc., Myriad Genetic Laboratories, Inc. and Quest Diagnostics on 11/03/2021
Lynch syndrome Submitted by Invitae on 01/15/2022
Criteria revisions Submitted by AliveAndKickn, Ambry Genetics, GeneDx, Illumina Inc., Myriad Genetic Laboratories, Inc., Quest Diagnostics and Volpara Health on 11/07/2022
Germline testing Submitted by Ambry Genetics, Illumina Inc., Myriad Genetic Laboratories, Inc. and Quest Diagnostics on 10/02/2023
Universal genetic testing Submitted by Invitae on 11/05/2023
Universal genetic testing Submitted by Invitae on 11/06/2023
Multi-cancer early detection (MCED) testing Submitted by GRAIL on 11/08/2023
Multi-cancer early detection (MCED) testing Submitted by GRAIL on 11/08/2023
Multi-cancer early detection (MCED) testing Submitted by GRAIL on 11/08/2023
Multi-cancer early detection (MCED) testing Submitted by GRAIL on 11/08/2023
Multi-cancer early detection (MCED) testing Submitted by GRAIL on 11/08/2023
Multi-cancer early detection (MCED) testing Submitted by GRAIL on 11/08/2023

Head and Neck Cancers Panel

Radiation Therapy Submitted by American Society for Radiation Oncology on 05/28/2020
Pembrolizumab Submitted by Merck & Co., Inc. on 06/17/2020
NCCN Evidence Blocks Submitted by Merck & Co., Inc. on 06/18/2020
TMB Submitted by Foundation Medicine, Inc. on 06/22/2020
TMB Submitted by Foundation Medicine, Inc. on 09/15/2020
Next generation sequencing Submitted by Kura Oncology, Inc. on 04/29/2021
Tumor mutational burden Submitted by Illumina Inc. on 05/13/2021
Polymerized Cross-Linked Sucralfate (PCLS) Submitted by Translational Medicine Clinic & Research Center, LLC on 05/20/2021
Circulating cell-free DNA Submitted by Grail, Inc. on 05/28/2021
Lymphedema Submitted by Vanderbilt University School of Nursing on 05/28/2021
Fam-trastuzumab deruxtecan-nxki Submitted by AstraZeneca and Daiichi-Sankyo, Inc. on 06/11/2021
Nivolumab + Ipilimumab Submitted by Bristol-Myers Squibb Company on 09/20/2021
The survival benefit of lymph node dissection in resected T1-2, cN0 supraglottic cancer: A population-based propensity score matching analysis Submitted by Sun Yat-sen University Cancer Center on 02/25/2022
Comparison of survival outcomes among patients with T1–2 cN0 oropharyngeal cancer treated with or without elective neck dissection Submitted by Sun Yat-sen University Cancer Center on 02/25/2022
Nivolumab + Ipilimumab Submitted by Bristol-Myers Squibb Company on 04/11/2022
Plasma-Based Comprehensive Genomic Profiling (CGP) Submitted by Guardant Health on 06/01/2022
Selpercatinib Submitted by Eli Lilly and Company on 09/21/2022
Pembrolizumab, carboplatin, and paclitaxel Submitted by Merck & Co., Inc. on 11/08/2022
Transoral Surgery Submitted by ECOG-ACRIN Cancer Research Group on 11/14/2022
Goserelin Submitted by TerSera Therapeutics on 02/16/2023
Nivolumab plus ipilimumab Submitted by Bristol-Myers Squibb Company on 03/17/2023
Cabozantinib Submitted by Exelixis Inc. on 04/24/2023
TTMV-HPV DNA Submitted by Naveris on 04/28/2023
Toripalimab-tpzi Submitted by Coherus BioSciences on 10/30/2023
Biomarker Testing Submitted by Merck & Co., Inc. on 10/31/2023
Erdafitinib Submitted by Janssen Scientific Affairs on 11/13/2023
Circulating HPV tumor DNA Submitted by Naveris Inc on 03/11/2024
tislelizumab plus cisplatin/gemcitabine Submitted by BeiGene USA on 03/14/2024
tislelizumab Submitted by BeiGene USA on 03/14/2024
MCED Submitted by GRAIL on 03/23/2024
MCED Submitted by GRAIL on 03/23/2024
MCED Submitted by GRAIL on 03/23/2024
MCED Submitted by GRAIL on 03/23/2024
MCED Submitted by GRAIL on 03/23/2024
MCED Submitted by GRAIL on 03/23/2024
MCED Submitted by GRAIL on 03/23/2024
MCED Submitted by GRAIL on 03/23/2024
ctHPVDNA Submitted by HPV Cancers Alliance on 03/25/2024
ctHPVDNA Submitted by Medical University of South Carolina and Naveris on 03/27/2024
Cyclophosphamide/doxorubicin/vincristine Submitted by Evicore on 05/28/2024
Repotrectinib Submitted by BMS on 06/14/2024

Hematopoietic Cell Transplantation Panel

Defibrotide sodium Submitted by Jazz Pharmaceuticals Inc. on 10/22/2020
Belumosudil Submitted by Kadmon Corporation LLC on 07/21/2021
Ruxolitinib Submitted by Incyte Corporation on 09/23/2021
Abatacept Submitted by Bristol-Myers Squibb Company on 12/14/2021
Ibrutinib Submitted by Pharmacyclics, LLC on 09/20/2022
TempTraq Submitted by Blue Spark Technologies on 09/29/2022
Fostamatinib Submitted by Rigel Pharmaceuticals, Inc.  on 03/10/2023
Omidubicel-onlv Submitted by Gamida Cell, Inc on 05/08/2023
Continuous temperature monitoring Submitted by Blue Spark Technologies on 09/12/2023
Motixafortide + filgrastim (G-CSF) Submitted by BioLineRx on 09/22/2023
Abatacept Submitted by Bristol-Myers Squibb Company on 10/05/2023
Axatilimab Submitted by Incyte on 08/15/2024

Hematopoietic Growth Factors Panel

Eflapegrastim-xnst Submitted by Spectrum Pharmaceuticals, Inc. on 08/31/2020
Granulocyte Colony Stimulating Factors (G-CSF) Submitted by The University of Arizona Cancer Center on 09/17/2020
Pegfilgrastim Submitted by Coherus BioSciences on 09/17/2020
Trilaciclib Submitted by G1 Therapeutics on 09/18/2020
Ferric Derisomaltose Submitted by Pharmacosmos Therapeutics, Inc. on 09/21/2020
cabazitaxel Submitted by Sanofi on 01/29/2021
Trilaciclib Submitted by G1 Therapeutics on 02/12/2021
ferric derisomaltose Submitted by Pharmacosmos Therapeutics, Inc. on 03/09/2021
plinabulin_pegfilgrastin Submitted by BeyondSpring Pharmaceuticals, Inc. on 09/15/2021
Pegfilgrastim Submitted by on 09/28/2021
ferric carboxymaltose Submitted by American Regent on 03/24/2022
FOLFOX Submitted by eviCore Healthcare on 07/15/2022
eflapegrastim-xnst Submitted by Spectrum Pharmaceuticals, Inc. on 08/03/2022
Ferric derisomaltose Submitted by Pharmacosmos Therapeutics, Inc. on 12/20/2022
Noninvasive continuous temperature monitoring Submitted by Blue Spark Technologies on 05/03/2023
Cetirizine Hydrochloride for Injection Submitted by TerSera on 04/23/2024
Cetirizine Hydrochloride for Injection Submitted by TerSera on 04/23/2024

Hepatobiliary Cancers Panel

Lenvatinib Submitted by Eisai Inc. on 05/29/2020
Pembrolizumab Submitted by Merck & Co., Inc. on 06/17/2020
Tumor Mutational Burden (TMB) Submitted by Foundation Medicine, Inc. on 06/22/2020
Lenvatinib Submitted by Eisai Inc. on 08/12/2020
Radioembolization Submitted by Society of Interventional Oncology on 10/01/2020
Ipilimumab Submitted by Bristol-Myers Squibb Company on 10/02/2020
Pralsetinib Submitted by Blueprint Medicines on 10/02/2020
Dabrafenib + Trametinib Submitted by Novartis Pharmaceuticals Corporation on 10/08/2020
Cabozantinib Submitted by Exelixis Inc. on 04/27/2021
Pembrolizumab Submitted by Merck & Co., Inc. on 06/18/2021
Nivolumab Submitted by Bristol-Myers Squibb Company on 07/06/2021
Nivolumab Submitted by Bristol-Myers Squibb Company on 07/26/2021
Trastuzumab + pertuzumab Submitted by Genentech, Inc. on 08/11/2021
Dostarlimab-gxly Submitted by GlaxoSmithKline on 08/17/2021
Galleri Submitted by Grail, Inc. on 09/07/2021
Ivosidenib Submitted by Servier Pharmaceuticals LLC on 09/08/2021
Radioembolization Submitted by Society of Interventional Oncology on 09/08/2021
Cabozantinib Submitted by Exelixis Inc. on 09/16/2021
Pembrolizumab Submitted by Merck & Co., Inc. on 09/22/2021
Liposomal irinotecan Submitted by Ipsen Biopharmaceuticals, Inc. on 11/24/2021
Nivolumab Submitted by Bristol-Myers Squibb Company on 12/16/2021
Durvalumab + gemcitabine + cisplatin Submitted by AstraZeneca on 01/21/2022
Durvalumab Submitted by AstraZeneca on 01/21/2022
Pembrolizumab monotherapy Submitted by Merck & Co., Inc. on 01/21/2022
Cemiplimab Submitted by Regeneron Pharmaceuticals, Inc. and Sanofi on 02/17/2022
Atezolizumab + Bevacizumab Submitted by Genentech, Inc. on 04/06/2022
Nivolumab + Ipilimumab Submitted by Bristol-Myers Squibb Company on 04/11/2022
ASTRO Link Submitted by American Society for Radiation Oncology on 04/26/2022
Durvalumab + gemcitabine + cisplatin Submitted by AstraZeneca on 06/23/2022
T-DXd Submitted by AstraZeneca and Daiichi-Sankyo, Inc. on 07/05/2022
Durvalumab Submitted by AstraZeneca on 07/18/2022
Atezolizumab + Bevacizumab Submitted by Genentech, Inc. on 08/22/2022
Cabozantinib + Atezolizumab Submitted by Exelixis Inc. on 09/12/2022
Pembrolizumab + Lenvatinib Submitted by Merck & Co., Inc. on 09/14/2022
ASTRO Review Submitted by American Society for Radiation Oncology on 09/19/2022
Selpercatinib Submitted by Eli Lilly and Company on 09/21/2022
Thermal Ablation Submitted by Society of Interventional Oncology on 09/30/2022
Pembrolizumab Submitted by eviCore Healthcare on 09/30/2022
Futibatinib Submitted by Taiho Oncology, Inc. on 10/03/2022
CGP Submitted by Guardant Health on 10/14/2022
CGP Submitted by Foundation Medicine, Inc. on 10/18/2022
Oncoguard Submitted by Community Liver Alliance on 10/20/2022
Tremelimumab-actl plus durvalumab Submitted by AstraZeneca on 10/24/2022
Ivosidenib Submitted by Servier Pharmaceuticals LLC on 11/15/2022
Futibatinib Submitted by Taiho Oncology, Inc. on 01/24/2023
Sodium thiosulfate Submitted by Fennec Pharma on 02/15/2023
Pembrolizumab Submitted by Merck & Co., Inc. on 04/17/2023
Atezo + bev Submitted by Genentech, Inc. on 04/17/2023
Adagrasib Submitted by Mirati Therapeutics, Inc. on 04/26/2023
T-DXd Submitted by AstraZeneca and Daiichi-Sankyo, Inc. on 06/06/2023
Lenvatinib Submitted by Eisai Inc. on 07/05/2023
Neratnib Submitted by Puma Biotechnology on 09/07/2023
Tucatinib plus trastuzumab Submitted by Seagen Inc on 09/19/2023
CDx Submitted by Guardant Health on 09/21/2023
Cabozantinib tablets Submitted by Exelixis Inc. on 09/21/2023
Atezolizumab + Bevacizumab Submitted by Genentech on 11/01/2023
tislelizumab Submitted by BeiGene USA on 03/14/2024
tislelizumab Submitted by BeiGene USA on 03/14/2024
Camrelizumab + Rivoceranib Submitted by Elevar Therapeutics on 04/02/2024
Fam-Trastuzumab Deruxtecan-nxki Submitted by Daiichi Sankyo, Inc. and AstraZeneca on 04/08/2024
Repotrectinib Submitted by BMS on 06/14/2024
Repotrectinib Submitted by BMS on 06/14/2024
Atezolizumab and Hyaluronidase-tqjs Submitted by Genentech on 09/12/2024

Histiocytic Neoplasms Panel

Selpercatinib Submitted by Eli Lilly and Company on 09/21/2022

Hodgkin Lymphoma Panel

Pembrolizumab Submitted by Merck & Co., Inc. on 05/29/2020
Pembrolizumab Submitted by Merck & Co., Inc. on 10/15/2020
Pembrolizumab Submitted by Merck & Co., Inc. on 04/08/2021
Brentuximab vedotin + AVD Submitted by Seagen Inc on 07/22/2021
Brentuximab vedotin + AVD (BV+AVD) Submitted by Seagen Inc on 07/14/2022
Nivolumab Submitted by Bristol-Myers Squibb Company on 03/14/2023
Nivolumab Submitted by Bristol-Myers Squibb Company on 07/24/2023
BrECADD Submitted by Seagen Inc on 08/28/2023
Brentuximab Vedotin with Nivolumab Submitted by Pfizer on 12/12/2023
Nivolumab Submitted by BMS on 01/16/2024
tislelizumab Submitted by BeiGene USA on 03/14/2024
Brentuximab Vedotin Submitted by Pfizer on 07/15/2024
Nivolumab Submitted by BMS on 10/17/2024

Kidney Cancer Panel

Nivolumab Submitted by Bristol-Myers Squibb Company on 09/13/2020
Lenvatinib + Pembrolizumab Submitted by Eisai Inc. on 09/24/2020
Nivolumab + Ipilimumab Submitted by Bristol-Myers Squibb Company on 12/07/2020
Nivolumab + Cabozantinib Submitted by Bristol-Myers Squibb Company on 01/25/2021
Nivolumab + Cabozantinib Submitted by Exelixis Inc. on 01/25/2021
Pembrolizumab Submitted by Merck & Co., Inc. on 02/04/2021
Nivolumab + Ipilimumab Submitted by Bristol-Myers Squibb Company on 02/11/2021
Lenvatinib + pembrolizumab Submitted by Eisai Inc. on 02/13/2021
Lenvatinib + Everolimus Submitted by Eisai Inc. on 02/13/2021
Nivolumab + Cabozantinib Submitted by Bristol-Myers Squibb Company on 03/04/2021
Cabozantinib + Nivolumab Submitted by Exelixis Inc. on 03/05/2021
Cabozantinib Submitted by Exelixis Inc. on 03/08/2021
Tivozanib Submitted by AVEO Oncology on 03/12/2021
Management of T1a renal masses Submitted by Society of Interventional Oncology on 03/31/2021
Cabozantinib Submitted by Exelixis Inc. on 04/15/2021
Tivozanib Submitted by AVEO Oncology on 04/16/2021
Tivozanib + Nivolumab Submitted by AVEO Oncology on 04/16/2021
Cabozantinib + Nivolumab Submitted by Bristol-Myers Squibb Company on 06/04/2021
Pembrolizumab Submitted by Merck & Co., Inc. on 06/07/2021
Nivolumab + Ipilimumab Submitted by Bristol-Myers Squibb Company on 06/07/2021
Belzutifan Submitted by Merck & Co., Inc. on 08/19/2021
Cabozantinib + Nivolumab Submitted by Exelixis Inc. on 09/02/2021
Pembrolizumab Submitted by Merck & Co., Inc. on 11/18/2021
Nivolumab + Ipilimumab Submitted by Bristol-Myers Squibb Company on 12/14/2021
Thermal Ablation Submitted by Society of Interventional Oncology on 02/11/2022
Tivozanib Submitted by AVEO Oncology on 03/08/2022
Tivozanib Submitted by AVEO Oncology on 03/08/2022
Tumor Testing Submitted by Ambry Genetics, GeneDx Inc, Myriad Genetic Laboratories Inc, Quest Diagnostics Laboratories and AliveAndKickn on 03/17/2022
Cabozantinib + Nivolumab Submitted by Exelixis Inc. on 03/21/2022
Nivolumab + Ipilimumab Submitted by Bristol-Myers Squibb Company on 05/17/2022
Treatment Clarification Submitted by Ambry Genetics, GeneDx Inc, Myriad Genetic Laboratories Inc, Quest Diagnostics Laboratories and AliveAndKickn on 08/24/2022
Pembrolizumab + Lenvatinib Submitted by Merck & Co., Inc. on 09/15/2022
Thermal Ablation Submitted by Society of Interventional Oncology on 03/08/2023
Genetic Testing Submitted by Ambry Genetics, GeneDx, Illumina, Myriad Genetics, Quest Diagnostics, and Volpara Health on 03/13/2023
Thermal Ablation Submitted by Society of Interventional Radiology on 03/21/2023
Belzutifan Submitted by Merck & Co., Inc. on 10/31/2023
belzutifan Submitted by Merck & Co., Inc. on 12/18/2023
Pembrolizumab + lenvatinib Submitted by Merck & Co., Inc. on 02/07/2024
Toripalimab/Axitinib Submitted by Coherus Biosciences on 03/26/2024
Toripalimab/Axitinib Submitted by Coherus Biosciences on 03/26/2024
Pembrolizumab Submitted by Merck & Co., Inc. on 04/19/2024
Pembrolizumab Submitted by Merck & Co., Inc. on 04/19/2024

Lung Cancer Screening Panel

Percepta GSC Submitted by Veracyte, Inc. on 05/05/2022
Nodify XL2 Test Submitted by Biodesix on 05/20/2024

Management of Immunotherapy-Related Toxicity Panel

Guardant360 Submitted by Guardant Health on 06/15/2020
Sargramostim Submitted by Partner Therapeutics on 06/17/2021
Cetirizine Submitted by Dr. Rex Garland, DO & Dr. Michael S. Blaiss, MD on 07/08/2021
nivolumab and relatlimab-rmbw Submitted by Bristol-Myers Squibb Company on 06/10/2022
Intravenous (IV) cetirizine hydrochloride Submitted by TerSera Therapeutics on 06/30/2022
mosunetuzumab Submitted by Genentech, Inc. on 12/23/2022
IV Cetirizine Submitted by TerSera Therapeutics on 05/16/2023
Continuous temperature monitoring Submitted by Blue Spark Technologies on 05/18/2023

Melanoma Panel

Footnote and gene mutation listings Submitted by Myriad Genetic Laboratories, Inc. on 06/09/2020
Pembrolizumab weight-based dosing Submitted by Value in Cancer Care Consortium (Vi3C) on 06/10/2020
GEP using DecisionDx-UM for Uveal Melanoma Submitted by Castle Biosciences on 06/15/2020
Pembrolizumab and low-dose ipilimumab for second- or subsequent line therapy Submitted by Merck & Co., Inc. on 06/16/2020
Pigmented lesion assay (PLA) Submitted by DermTech, Inc. on 06/16/2020
DecisionDx-Melanoma test (31-GEP) Submitted by Castle Biosciences on 06/17/2020
PLA Submitted by Dermatologic Surgery Center of Washington, LLC on 06/21/2020
Tumor mutation burden (TMB) measurement Submitted by Foundation Medicine, Inc. on 06/22/2020
Gene expression profiling (GEP) Submitted by Myriad Genetic Laboratories, Inc. on 06/22/2020
PLA Submitted by SUNY Downstate on 06/22/2020
PLA Submitted by University of Pittsburgh School of Medicine Department of Dermatology on 06/23/2020
PLA Submitted by Northwestern University Feinberg School of Medicine, Department of Dermatology on 06/23/2020
Pembrolizumab and low-dose ipilimumab for first-line Submitted by Merck & Co., Inc. on 07/21/2020
Atezolizumab in combination with cobimetinib and vemurafenib for Cutaneous Melanoma Submitted by Genentech, Inc. on 07/30/2020
Pembrolizumab Submitted by Merck & Co., Inc. on 08/12/2020
Tumor mutation burden (TMB) measurement Submitted by Foundation Medicine, Inc. on 09/15/2020
Pembrolizumab Submitted by Merck & Co., Inc. on 01/06/2021
Liquid biopsy-based DNA testing Submitted by Illumina Inc. on 05/28/2021
Nivolumab Submitted by Bristol-Myers Squibb Company on 06/04/2021
Nivolumab and Ipilimumab Submitted by Bristol-Myers Squibb Company on 06/04/2021
Nivolumab and Ipilimumab Submitted by Bristol-Myers Squibb Company on 06/06/2021
Pembrolizumab and Lenvatinib Submitted by Merck & Co., Inc. on 06/07/2021
Pembrolizumab Submitted by Merck & Co., Inc. on 06/07/2021
GEP Testing Submitted by Castle Biosciences on 06/11/2021
Adjuvant RT Submitted by American Society for Radiation Oncology on 06/11/2021
Pigmented lesion assay Submitted by DermTech, Inc. on 06/11/2021
Ipilimumab and sargramostim Submitted by Partner Therapeutics on 06/11/2021
Genomic patch testing Submitted by Georgetown University on 06/13/2021
Ripretinib for tumors with activating mutations of KIT (Cutaneous Melanoma) Submitted by Deciphera Pharmaceuticals, Inc. on 09/16/2021
Tebentafusp Submitted by Immunocore on 10/29/2021
Pembrolizumab Submitted by Merck & Co., Inc. on 11/21/2021
Pembrolizumab (Cutaneous Melanoma) Submitted by Merck & Co., Inc. on 12/02/2021
Pembrolizumab Submitted by Merck & Co., Inc. on 12/03/2021
Nivolumab plus Ipilimumab (Cutaneous Melanoma) Submitted by Bristol-Myers Squibb Company on 12/09/2021
Nivolumab plus Ipilimumab (Cutaneous Melanoma) Submitted by Bristol-Myers Squibb Company on 12/10/2021
Pembrolizumab and lenvatinib (Cutaneous Melanoma) Submitted by Merck & Co., Inc. on 01/25/2022
Nivolumab and relatlimab-rmbw Submitted by Bristol-Myers Squibb Company on 03/18/2022
Nivolumab and relatlimab-rmbw (Cutaneous Melanoma) Submitted by Bristol-Myers Squibb Company on 05/12/2022
Pembrolizumab (Cutaneous Melanoma) Submitted by Merck & Co., Inc. on 06/10/2022
Gene expression profiling (Melanoma: Cutaneous) Submitted by Castle Biosciences on 06/12/2022
Nivolumab and relatlimab-rmbw (Cutaneous Melanoma) Submitted by Bristol-Myers Squibb Company on 06/15/2022
Nivolumab with Ipilimumab (Cutaneous Melanoma) Submitted by Bristol-Myers Squibb Company on 06/15/2022
Cutaneous Melanoma Submitted by Guardant Health on 06/15/2022
Ripretinib for tumors with activating mutations of KIT (Cutaneous Melanoma) Submitted by Deciphera Pharmaceuticals, Inc. on 06/28/2022
GEP Testing for Uveal Melanoma Submitted by Castle Biosciences on 09/29/2022
Ipilimumab (Cutaneous Melanoma) Submitted by Bristol-Myers Squibb Company on 10/11/2022
Tezolizumab in combination with cobimetinib and vemurafenib (cutaneous melanoma) Submitted by Genentech, Inc. on 03/09/2023
Pembrolizumab (Cutaneous Melanoma) Submitted by Merck & Co., Inc. on 05/02/2023
Neoadjuvant pembrolizumab (Cutaneous Melanoma) Submitted by Merck & Co., Inc. on 05/04/2023
Pembrolizumab for unresectable desmoplastic melanoma (Cutaneous Melanoma) Submitted by Merck & Co., Inc. on 05/08/2023
Nivolumab and relatlimab-rmbw (Cutaneous Melanoma) Submitted by Bristol-Myers Squibb Company on 06/15/2023
Nivolumab and relatlimab-rmbw footnotes (Cutaneous Melanoma) Submitted by Bristol-Myers Squibb Company on 06/15/2023
GEP test (Cutaneous Melanoma) Submitted by Castle Biosciences on 06/16/2023
Tebentafusp-tebn and durvalumab (Cutaneous Melanoma) Submitted by Immunocore on 06/16/2023
Intrathecal nivolumab (Cutaneous Melanoma) Submitted by The University of Texas MD Anderson Cancer Center on 06/25/2023
Nivolumab Submitted by Bristol-Myers Squibb Company on 10/16/2023
Lifileucel Submitted by Iovance and Iovance Biotherapeutics, Inc. on 02/21/2024
Lifileucel Submitted by Iovance and Iovance Biotherapeutics, Inc. on 02/21/2024
Lifileucel Submitted by Iovance and Iovance Biotherapeutics, Inc. on 02/21/2024
Atezolizumab and Hyaluronidase-tqjs Submitted by Genentech on 09/12/2024

Multiple Myeloma/Systemic Light Chain Amyloidosis/Waldenström Macroglobulinemia Panel

Daratumumab and Hyaluronidase-fihj Submitted by Janssen Scientific Affairs, LLC on 06/16/2020
Zanubrutinib Submitted by BeiGene, Ltd. on 07/31/2020
Belantamab mafodotin-blmf Submitted by GlaxoSmithKline on 08/05/2020
Carfilzomib Submitted by Amgen Inc. on 08/21/2020
Selinexor Submitted by Karyopharm Therapeutics on 11/12/2020
Ibrutinib Submitted by Pharmacyclics, LLC on 12/07/2020
Daratumumab and Hyaluronidase-fihj Submitted by Janssen Scientific Affairs, LLC on 02/01/2021
Melphalan flufenamide Submitted by Oncopeptides, Inc. on 03/01/2021
Ixazomib Submitted by Takeda Oncology on 03/24/2021
MRD assessment Submitted by Adaptive Biotechnologies on 03/25/2021
Idecabtagene Vicleucel Submitted by Bristol-Myers Squibb Company on 03/26/2021
Isatuximab Submitted by Sanofi on 03/31/2021
Selinexor + Dexamethasone Submitted by Karyopharm Therapeutics on 05/03/2021
Carfilzomib Submitted by Amgen Inc. on 05/18/2021
Pomalidomide Submitted by Bristol-Myers Squibb Company on 07/07/2021
Lenalidomide Submitted by Bristol-Myers Squibb Company on 07/15/2021
Daratumumab and Hyaluronidase-fihj Submitted by Janssen Scientific Affairs, LLC on 07/19/2021
Daratumumab Submitted by Janssen Scientific Affairs, LLC on 08/26/2021
elotuzumab Submitted by Bristol-Myers Squibb Company on 09/09/2021
Denosumab Submitted by Amgen Inc. on 09/22/2021
Selinexor_carfilzomib_dexamethasone Submitted by Karyopharm Therapeutics on 11/23/2021
blenrep Submitted by GlaxoSmithKline on 12/17/2021
isatuximab Submitted by Sanofi on 01/03/2022
cilta-cel Submitted by Janssen Biotech, Inc. on 03/02/2022
Gene expression profiling Submitted by SkylineDX on 03/30/2022
daratumumab monotherapy footnote/reference addition Submitted by Janssen Scientific Affairs, LLC on 09/29/2022
isatuximab Submitted by Sanofi on 11/21/2022
Belantamab mafodotin-blmf Submitted by GlaxoSmithKline on 11/22/2022
selinexor, bortezomib and dexamethasone for use in lenalidomide-refractory multiple myeloma. Submitted by Karyopharm Therapeutics on 03/18/2023
Talquetamab Submitted by Janssen Scientific Affairs, LLC on 06/19/2023
Elranatamab Submitted by Pfizer Inc. on 08/15/2023
Daratumumab in combination with Lenalidomide, Bortezomib, and Dexamethasone Submitted by Janssen Scientific Affairs on 12/12/2023
Daratumumab in combination with Lenalidomide Submitted by Janssen Scientific Affairs on 12/12/2023
Ciltacabtagene autoleucel Submitted by Janssen Scientific Affairs on 12/21/2023
Ciltacabtagene autoleucel Submitted by Janssen Scientific Affairs on 12/21/2023
Ibrutinib + Rituximab Submitted by AbbVie Inc. on 01/24/2024
Isatuximab/Carfilzomib/Lenalidomide/Dexamethasone Submitted by Amgen on 02/12/2024
Ixazomib plus lenalidomide and dexamethasone Submitted by Takeda Oncology on 03/04/2024
SCIG formulations Submitted by CSL Behring on 03/18/2024
SCIG formulations Submitted by CSL Behring on 03/18/2024
Idecabtagene Vicleucel Submitted by BMS on 04/06/2024
Tidecabtagene Vicleucel Submitted by BMS on 04/06/2024
Ciltacabtagene autoleucel Submitted by Janssen Scientific Affairs on 04/08/2024
Bortezomib and Dexamethasone Submitted by Sanofi on 06/05/2024
Daratumumab in combination with Lenalidomide, Bortezomib, and Dexamethasone Submitted by Janssen Scientific Affairs on 07/31/2024
Daratumumab in combination with Lenalidomide, Bortezomib, and Dexamethasone Submitted by Janssen Scientific Affairs on 07/31/2024

Myelodysplastic Syndromes Panel

Decitabine and Cedazuridine Submitted by Taiho Oncology, Inc. on 07/10/2020
Comprehensive Genomic Profiling Submitted by Foundation Medicine, Inc. on 03/12/2021
Luspatercept-aamt Submitted by Bristol-Myers Squibb Company on 04/01/2021
Luspatercept-aamt Submitted by Bristol-Myers Squibb Company on 12/13/2021
luspatercept Submitted by Bristol-Myers Squibb Company on 12/13/2022
omidubicel-only Submitted by Gamida Cell, Inc on 04/28/2023
CGP Submitted by Foundation Medicine, Inc. on 05/12/2023
luspatercept Submitted by Bristol-Myers Squibb Company on 06/12/2023
luspatercept Submitted by Bristol-Myers Squibb Company on 08/29/2023
luspatercept-aamt Submitted by Bristol-Myers Squibb Company on 09/09/2023
Ivosidenib Submitted by Servier Pharmaceuticals LLC on 10/25/2023
Avapritinib Submitted by Blueprint Medicines on 11/15/2023
Olutasidenib Submitted by on 01/02/2024
Olutasidenib Submitted by Rigel Pharmaceuticals on 01/02/2024
Olutasidenib Submitted by Rigel Pharmaceuticals on 01/02/2024
Olutasidenib Submitted by Rigel Pharmaceuticals on 01/02/2024
Decitabine and cedazuridine Submitted by Taiho Oncology on 03/05/2024
Testing for mIDH1 Submitted by Servier Pharmaceuticals on 03/27/2024
Testing for mIDH1 Submitted by Servier Pharmaceuticals on 03/28/2024
Testing for mIDH1 Submitted by Servier Pharmaceuticals on 03/28/2024
Testing for mIDH1 Submitted by Servier Pharmaceuticals on 03/28/2024
Imetelstat Submitted by Geron on 05/14/2024
Imetelstat Submitted by Geron on 05/14/2024
Genomic Profiling (CGP) Submitted by Access to Comprehensive Genomic Profiling (ACGP), Illumina Inc., LabCorp, Loxo@Lilly, Merck & Co., Inc., NeoGenomics, Roche Diagnostic Corporation, Tempus and ThermoFisher Scientific on 05/16/2024
Luspatercept-aamt Submitted by BMS on 07/22/2024
Luspatercept-aamt Submitted by BMS on 09/10/2024

Myeloproliferative Neoplasms Panel

Comprehensive genomic profiling Submitted by Foundation Medicine, Inc. on 07/16/2020
Avapritinib Submitted by Blueprint Medicines on 06/17/2021
Pacritinib Submitted by CTI BioPharma Corp. on 07/08/2021
Ropeginterferon alfa-2b-njft (Polycythemia Vera) Submitted by PharmaEssentia Corporation on 11/14/2021
Ropeginterferon alfa-2b-njft Submitted by PharmaEssentia Corporation on 07/14/2022
Pacritinib Submitted by CTI BioPharma Corp. on 07/19/2022
Pemigatinib (MLNE) Submitted by Incyte Corporation on 08/01/2022
Cetirizine/IV Oral Antihistamines Submitted by TerSera Therapeutics on 03/06/2023
Pacritinib Submitted by CTI BioPharma Corp. on 05/15/2023
Avapritinib Submitted by Blueprint Medicines on 05/23/2023
IV cetirizine Submitted by TerSera Therapeutics on 06/06/2023
Avapritinib Submitted by Blueprint Medicines on 06/13/2023
Ropeginterferon alfa-2b-njft Submitted by PharmaEssentia Corporation on 07/18/2023
Momelotinib Submitted by GlaxoSmithKline on 07/21/2023

Neuroblastoma Panel

Neuroendocrine Tumors Panel

Pembrolizumab Submitted by Merck & Co., Inc. on 06/17/2020
SSR PET tracer options Submitted by Curium on 09/03/2020
Pralsetinib Submitted by Blueprint Medicines on 09/10/2020
TMB and pembrolizumab Submitted by Foundation Medicine, Inc. on 09/18/2020
Liver Directed Therapy Submitted by Society of Interventional Oncology on 10/08/2020
Principles of Hormone Control Submitted by TerSera Therapeutics on 10/27/2020
cabozantinib Submitted by Exelixis Inc. on 06/09/2021
lenvatinib Submitted by Eisai Inc. on 06/25/2021
Dostarlimab-gxly Submitted by GlaxoSmithKline on 08/17/2021
Belzutifan Submitted by Merck & Co., Inc. on 08/19/2021
PRRT Lu DOTATATE Submitted by Novartis Pharmaceuticals Corporation on 09/22/2021
Telotristat ethyl Submitted by TerSera Therapeutics on 10/28/2021
Letetium Lu dotatate Submitted by Novartis Pharmaceuticals Corporation on 01/18/2022
belzutifan Submitted by Merck & Co., Inc. on 03/10/2022
lanreotide injection Submitted by Ipsen Biopharmaceuticals, Inc. on 03/11/2022
lanreotide Submitted by Ipsen Biopharmaceuticals, Inc. on 03/11/2022
nivolumab in combination with ipilimumab Submitted by Bristol-Myers Squibb Company on 04/11/2022
Tecentriq in combination with Avastin Submitted by Genentech, Inc. on 09/07/2022
PRRT PPQ Submitted by Wren Laboratories on 06/26/2023
NETest_Surgery Submitted by Wren Laboratories on 06/26/2023
NETest_Monitor Submitted by Wren Laboratories on 06/26/2023
Lutetium Lu 177 dotatate Submitted by Novartis on 02/06/2024
Lutetium Lu 177 dotatate Submitted by Novartis on 02/06/2024
Lutetium Lu 177 dotatate Submitted by Novartis on 02/06/2024
Lutetium Lu 177 dotatate Submitted by Novartis on 02/06/2024
Lutetium Lu 177 dotatate Submitted by Novartis on 02/06/2024
Lutetium Lu 177 dotatate Submitted by Novartis on 02/06/2024
Lutetium Lu 177 dotatate Submitted by Novartis on 02/06/2024
Lutetium Lu 177 dotatate Submitted by Novartis on 02/06/2024
Lutetium Lu 177 dotatate Submitted by Novartis on 02/06/2024
Lutetium Lu 177 dotatate Submitted by Novartis on 02/06/2024
Lutetium Lu 177 dotatate Submitted by Novartis on 05/21/2024
Repotrectinib Submitted by BMS on 06/14/2024
Repotrectinib Submitted by BMS on 06/14/2024
Repotrectinib Submitted by BMS on 06/14/2024
Repotrectinib Submitted by BMS on 06/14/2024
Repotrectinib Submitted by BMS on 06/14/2024
Repotrectinib Submitted by BMS on 06/14/2024
Repotrectinib Submitted by BMS on 06/14/2024
Selpercatinib Submitted by Eli Lilly and Company on 06/14/2024
Selpercatinib Submitted by Eli Lilly and Company on 06/14/2024
Resection of Primary and Metastatic Tumors Submitted by Yale New Haven Hospital on 06/22/2024
recurrence Submitted by Yale New Haven Hospital on 06/22/2024
Surgical Resection Submitted by Yale New Haven Hospital on 06/22/2024
PRRT-Related Risks Submitted by Yale New Haven Hospital on 06/22/2024
Systemic Therapy Submitted by Yale New Haven Hospital on 06/22/2024
177-Lu-DOTATATE Submitted by Novartis on 08/02/2024
177-Lu-DOTATATE Submitted by Novartis on 08/02/2024
Pressure-Enabled Drug Delivery (PEDD) Submitted by Brown University School of Medicine and TriSalus Life Sciences on 08/06/2024
Liver-Directed Therapy Submitted by Society of Interventional Oncology (SIO) on 08/21/2024
Octreotide Acetate Submitted by Sun Pharma on 09/20/2024
Octreotide Acetate Submitted by Sun Pharma on 09/20/2024
Octreotide Acetate Submitted by Sun Pharma on 09/20/2024
Octreotide Acetate Submitted by Sun Pharma on 09/20/2024
Octreotide Acetate Submitted by Sun Pharma on 09/20/2024
Octreotide Acetate Submitted by Sun Pharma on 09/20/2024
Cabozantinib Submitted by Exelixis on 09/24/2024
Cabozantinib Submitted by Exelixis on 09/24/2024
Cabozantinib Submitted by Exelixis on 09/24/2024

Non-Small Cell Lung Cancer/Mesothelioma/Thymomas and Thymic Carcinomas Panel

Atezolizumab Submitted by Genentech, Inc. on 05/20/2020
Nivolumab + Ipilimumab Submitted by Bristol-Myers Squibb Company on 05/26/2020
Brigatinib Submitted by Takeda Oncology on 05/26/2020
Nivolumab + Ipilimumab Submitted by Bristol-Myers Squibb Company on 05/29/2020
Osimertinib Submitted by AstraZeneca on 05/31/2020
Pembrolizumab Submitted by Value in Cancer Care Consortium (Vi3C) on 06/10/2020
T-DXd Submitted by Daiichi-Sankyo, Inc. on 06/15/2020
Tumor Mutational Burden (TMB) Submitted by Foundation Medicine, Inc. on 06/22/2020
Key Recommendations Submitted by American Society for Radiation Oncology on 06/23/2020
Lenvatinib Submitted by Eisai Inc. on 06/23/2020
Comprehensive genomic profiling Submitted by Foundation Medicine, Inc. on 06/30/2020
Image-Guided Thermal Ablation (IGTA) Submitted by Society of Interventional Oncology on 07/01/2020
Guardant360 Submitted by Guardant Health on 07/02/2020
Tumor Treating Fields Submitted by Novocure on 07/03/2020
Bevacizumab Submitted by Genentech, Inc. on 07/06/2020
Brigatinib Submitted by Takeda Oncology on 07/07/2020
Capmatinib Submitted by Novartis Pharmaceuticals Corporation on 07/08/2020
Pembrolizumab Submitted by Merck & Co., Inc. on 07/13/2020
Nivolumab + Ipilimumab Submitted by Bristol-Myers Squibb Company on 08/08/2020
Pralsetinib Submitted by Blueprint Medicines on 09/08/2020
Tumor Mutational Burden (TMB) Submitted by Foundation Medicine, Inc. on 09/15/2020
Osimertinib Submitted by AstraZeneca on 09/19/2020
Selpercatinib Submitted by Eli Lilly and Company on 09/21/2020
Atezolizumab Submitted by Genentech, Inc. on 10/01/2020
Nivolumab + Ipilimumab Submitted by Bristol-Myers Squibb Company on 10/02/2020
Capmatinib Submitted by Novartis Pharmaceuticals Corporation on 11/04/2020
Lorlatinib Submitted by Pfizer Inc. on 11/19/2020
Durvalumab Submitted by AstraZeneca on 11/20/2020
Osimertinib Submitted by AstraZeneca on 12/21/2020
Nivolumab + Ipilimumab Submitted by Bristol-Myers Squibb Company on 01/18/2021
Nivolumab + Ipilimumab Submitted by Bristol-Myers Squibb Company on 01/21/2021
Integrated Classifier Submitted by Medical University of South Carolina on 01/27/2021
Tepotinib Submitted by EMD Serono on 02/04/2021
Atezolizumab Submitted by Genentech, Inc. on 02/09/2021
Cemiplimab Submitted by Regeneron Pharmaceuticals, Inc. on 02/16/2021
Osimertinib Submitted by AstraZeneca on 03/09/2021
NGS Submitted by AstraZeneca on 03/10/2021
Nivolumab Submitted by Bristol-Myers Squibb Company on 04/10/2021
Sotorasib Submitted by Amgen Inc. on 04/22/2021
Albumin-bound paclitaxel Submitted by Bristol-Myers Squibb Company on 05/14/2021
Amivantamab-vmjw Submitted by Janssen Biotech, Inc. on 05/24/2021
Afatinib Submitted by Boehringer Ingelheim on 05/26/2021
CGP Submitted by Illumina Inc. on 05/26/2021
Nivolumab_ipilimumab Submitted by Bristol-Myers Squibb Company on 06/04/2021
Pembrolizumab Submitted by Merck & Co., Inc. on 06/04/2021
DetermaRx Submitted by Oncocyte on 06/04/2021
Atezolizumab Submitted by Genentech, Inc. on 06/06/2021
Nivolumab Submitted by Bristol-Myers Squibb Company on 06/06/2021
CGP Submitted by Foundation Medicine, Inc. on 06/09/2021
Mobocertinib Submitted by Takeda Oncology on 06/10/2021
CGP Submitted by Guardant Health on 06/10/2021
Tepotinib Submitted by EMD Serono on 06/10/2021
Tepotinib METAmp Submitted by EMD Serono on 06/10/2021
Genetics Submitted by Myriad Genetic Laboratories, Inc. on 06/16/2021
Selpercatinib Submitted by Eli Lilly and Company on 06/17/2021
IGTA Submitted by Society of Interventional Oncology on 06/18/2021
Mobocertinib Submitted by Takeda Oncology on 09/16/2021
Atezolizumab Submitted by Genentech, Inc. on 09/20/2021
Osimertinib Submitted by AstraZeneca on 10/12/2021
Atezolizumab Submitted by Genentech, Inc. on 10/15/2021
Durvalumab Submitted by AstraZeneca on 10/19/2021
Pembrolizumab Submitted by Merck & Co., Inc. on 11/12/2021
Atezoliumab Submitted by Genentech, Inc. on 12/13/2021
Atezoliumab Submitted by Genentech, Inc. on 01/12/2022
Neoadjuvant Therapy Submitted by Champalimaud Foundation on 02/16/2022
Nivolumab + Chemotherapy Submitted by Bristol-Myers Squibb Company on 03/04/2022
Nivolumab + Ipilimumab Submitted by Bristol-Myers Squibb Company on 04/11/2022
Nivolumab + Chemotherapy Submitted by Bristol-Myers Squibb Company on 04/11/2022
Sotorasib Submitted by Amgen Inc. on 05/11/2022
Nivolumab + Ipilimumab Submitted by Bristol-Myers Squibb Company on 05/16/2022
Pembrolizumab + Ramucirumab Submitted by Merck & Co., Inc. on 06/03/2022
Pembrolizumab Submitted by Merck & Co., Inc. on 06/06/2022
Integrated Classifier Submitted by Biodesix on 06/07/2022
Nivolumab + Ipilimumab Submitted by Bristol-Myers Squibb Company on 06/08/2022
Durvalumab Submitted by AstraZeneca on 06/08/2022
Nivolumab + Ipilimumab + Chemotherapy Submitted by Bristol-Myers Squibb Company on 06/08/2022
Molecular Profiling Submitted by Foundation Medicine, Inc. on 06/09/2022
Pembrolizumab Submitted by Merck & Co., Inc. on 06/09/2022
Comprehensive Genomic Profiling Submitted by Guardant Health on 06/16/2022
Broad Molecular Profiling Submitted by Eli Lilly and Company on 06/17/2022
Dostarlimab-gxly Submitted by GlaxoSmithKline on 06/28/2022
Amivantamab-vmjw Submitted by Janssen Scientific Affairs, LLC on 07/05/2022
Fam-trastuzumab deruxtecan-nxki Submitted by AstraZeneca and Daiichi-Sankyo, Inc. on 08/12/2022
Capmatinib Submitted by Novartis Pharmaceuticals Corporation on 08/22/2022
Pembrolizumab + Lenvatinib Submitted by Merck & Co., Inc. on 09/07/2022
Pembrolizumab Submitted by Merck & Co., Inc. on 09/13/2022
Atezoliumab Submitted by Genentech, Inc. on 09/26/2022
Adagrasib Submitted by Mirati Therapeutics, Inc. on 10/31/2022
Nivolumab + Chemotherapy Submitted by Bristol-Myers Squibb Company on 11/08/2022
Cemiplimab-rwlc Submitted by Regeneron Pharmaceuticals, Inc. on 11/11/2022
Nivolumab + Ipilimumab + Chemotherapy Submitted by Genentech, Inc. on 11/11/2022
Durvalumab + Tremelimumab-actl Submitted by AstraZeneca on 11/14/2022
Tepotinib Submitted by EMD Serono on 12/01/2022
Tepotinib Submitted by EMD Serono on 12/13/2022
Pembrolizumab Submitted by Merck & Co., Inc. on 01/27/2023
Sotorasib Submitted by Amgen Inc. on 02/07/2023
Biomarker Testing Submitted by Amgen Inc. on 04/13/2023
Durvalumab Submitted by AstraZeneca on 04/17/2023
Cemiplimab-rwlc Submitted by Regeneron Pharmaceuticals, Inc. on 05/05/2023
Durvalumab Submitted by AstraZeneca on 05/12/2023
Comprehensive Genomic Profiling Submitted by Guardant Health on 05/31/2023
Pembrolizumab + Chemotherapy Submitted by Merck & Co., Inc. on 06/03/2023
Sotorasib Submitted by Amgen Inc. on 06/04/2023
Encorafenib + Binimetinib Submitted by Pfizer Inc. on 06/05/2023
Dostarlimab-gxly Submitted by GlaxoSmithKline on 06/05/2023
Osimertinib Submitted by AstraZeneca on 06/05/2023
Pembrolizumab Submitted by Merck & Co., Inc. on 06/05/2023
Pembrolizumab + Chemotherapy Submitted by Merck & Co., Inc. on 06/07/2023
Risk Prediction Submitted by Optellum on 06/08/2023
Fam-trastuzumab deruxtecan-nxki Submitted by AstraZeneca and Daiichi-Sankyo, Inc. on 06/09/2023
Image-guided thermal ablation Submitted by Society of Interventional Oncology on 06/09/2023
Nivolumab + Ipilimumab + Chemotherapy Submitted by Bristol-Myers Squibb Company on 06/09/2023
Amivantamab-vmjw Submitted by Janssen Scientific Affairs, LLC on 06/12/2023
Image-guided thermal ablation Submitted by Society of Interventional Radiology on 06/12/2023
Radiation Submitted by American Society for Radiation Oncology on 06/12/2023
Tumor Mutational Burden Submitted by Foundation Medicine, Inc. on 06/12/2023
Integrated Classifier Submitted by Biodesix on 06/13/2023
Adagrasib Submitted by Mirati Therapeutics, Inc. on 06/16/2023
Atezoliumab Submitted by Genentech, Inc. on 07/07/2023
Tumor Mutational Burden Submitted by Foundation Medicine, Inc. on 07/13/2023
Atezolizumab Submitted by Genentech, Inc. on 08/30/2023
Cemiplimab Submitted by Regeneron Pharmaceuticals, Inc. on 09/30/2023
Encorafenib + Binimetinib Submitted by Pfizer Inc. on 10/13/2023
Pembrolizumab + Chemotherapy Submitted by Merck & Co., Inc. on 10/17/2023
Selpercatinib Submitted by Eli Lilly and Company on 10/23/2023
Pembrolizumab + Chemotherapy Submitted by Merck & Co., Inc. on 10/24/2023
Durvalumab Submitted by AstraZeneca on 10/24/2023
Amivantamab-vmjw and Carboplatin-Pemetrexed Submitted by Janssen on 11/06/2023
Amivantamab-vmjw Submitted by Janssen Scientific Affairs on 11/07/2023
Osimertinib plus platinum-pemetrexed Submitted by AstraZeneca on 11/12/2023
Erdafitinib Submitted by Janssen Scientific Affairs on 11/15/2023
Repotrectinib Submitted by BMS on 11/15/2023
Pembrolizumab Submitted by Merck & Co., Inc. on 11/16/2023
Amivantamab-vmjw and Carboplatin-Pemetrexed Submitted by Janssen on 11/21/2023
Dostarlimab-gxly Submitted by GSK on 12/06/2023
Dostarlimab-gxly Submitted by GSK on 12/06/2023
Dostarlimab-gxly Submitted by GSK on 12/06/2023
Dostarlimab-gxly Submitted by GSK on 12/06/2023
Dostarlimab-gxly Submitted by GSK on 12/06/2023
Toripalimab/pemetrexed/cisplatin or carboplatin Submitted by Coherus Biosciences on 12/18/2023
Toripalimab/pemetrexed/cisplatin or carboplatin Submitted by Coherus Biosciences on 12/18/2023
Repotrectinib Submitted by BMS on 01/11/2024
Sotorasib Submitted by university of michigan; veterans affairs center for clinical management research on 02/13/2024
Osimertinib plus Platinum-Pemetrexed Submitted by AstraZeneca on 02/20/2024
Osimertinib plus Platinum-Pemetrexed Submitted by AstraZeneca on 02/20/2024
Osimertinib plus Platinum-Pemetrexed Submitted by AstraZeneca on 02/20/2024
Osimertinib plus Platinum-Pemetrexed Submitted by AstraZeneca on 02/20/2024
Osimertinib plus Platinum-Pemetrexed Submitted by AstraZeneca on 02/20/2024
Tislelizumab Submitted by BeiGene USA on 03/14/2024
Fam-Trastuzumab Deruxtecan-nxki Submitted by Daiichi Sankyo, Inc. and AstraZeneca on 04/08/2024
Fam-Trastuzumab Deruxtecan-nxki Submitted by Daiichi Sankyo, Inc. and AstraZeneca on 04/08/2024
Fam-Trastuzumab Deruxtecan-nxki Submitted by Daiichi Sankyo, Inc. and AstraZeneca on 04/08/2024
Alectinib Submitted by Genentech on 04/11/2024
Molecular Testing Submitted by Genentech on 04/11/2024
Repotrectinib Submitted by BMS on 04/17/2024
Nivolumab + Chemotherapy Submitted by BMS on 05/16/2024
Nivolumab + Chemotherapy Submitted by BMS on 05/16/2024
Alectinib Submitted by Genentech on 05/29/2024
Osimertinib Submitted by Astrazeneca on 06/03/2024
Osimertinib Submitted by Astrazeneca on 06/03/2024
Osimertinib Submitted by Astrazeneca on 06/03/2024
Osimertinib Submitted by Astrazeneca on 06/03/2024
Osimertinib Submitted by Astrazeneca on 06/03/2024
Osimertinib Submitted by Astrazeneca on 06/03/2024
Pembrolizumab plus cCRT Submitted by Merck & Co., Inc. on 06/03/2024
Pembrolizumab plus cCRT Submitted by Merck & Co., Inc. on 06/03/2024
Pembrolizumab plus cCRT Submitted by Merck & Co., Inc. on 06/03/2024
Pembrolizumab plus cCRT Submitted by Merck & Co., Inc. on 06/03/2024
Pembrolizumab plus cCRT Submitted by Merck & Co., Inc. on 06/03/2024
Pembrolizumab plus cCRT Submitted by Merck & Co., Inc. on 06/03/2024
Toripalimab Submitted by Coherus Biosciences on 06/05/2024
Toripalimab Submitted by Coherus Biosciences on 06/05/2024
Toripalimab Submitted by Coherus Biosciences on 06/05/2024
Pafolacianine Submitted by On Target Lab on 06/05/2024
Sacituzumab govitecan-hziy Submitted by Gilead Sciences on 06/07/2024
Malignancy Risk Prediction Models Submitted by Optellum Inc. on 06/07/2024
Malignancy Risk Prediction Models Submitted by Optellum Inc. on 06/07/2024
Pafolacianine Submitted by On Target Lab on 06/09/2024
Multi-cancer early detection (MCED) testing Submitted by GRAIL and Grail, Inc. on 06/10/2024
Multi-cancer early detection (MCED) testing Submitted by GRAIL and Grail, Inc. on 06/10/2024
Lorlatinib Submitted by Pfizer on 06/11/2024
Germline Genetic Multigene Panel Testing” Submitted by Invitae, Center for Precision Medicine, Investigational Cancer Therapeutics and Thoracic Oncology Department of Medicine University of Colorado, Sarah Cannon Research Institute (SCRI), Stephenson Cancer Center University of Oklahoma and Steven Sorscher, MD Medical Oncologist on 06/11/2024
Broad Molecular Profiling Submitted by Foundation Medicine, Inc. on 06/13/2024
Broad Molecular Profiling Submitted by Foundation Medicine, Inc. on 06/13/2024
Broad Molecular Profiling Submitted by Foundation Medicine, Inc. on 06/13/2024
Broad Molecular Profiling Submitted by Foundation Medicine, Inc. on 06/13/2024
Broad Molecular Profiling Submitted by Foundation Medicine, Inc. on 06/13/2024
Broad Molecular Profiling Submitted by Foundation Medicine, Inc. on 06/13/2024
Broad Molecular Profiling Submitted by Foundation Medicine, Inc. on 06/13/2024
Broad Molecular Profiling Submitted by Foundation Medicine, Inc. on 06/13/2024
Repotrectinib Submitted by BMS on 06/13/2024
Repotrectinib Submitted by BMS on 06/13/2024
Repotrectinib Submitted by BMS on 06/14/2024
Repotrectinib Submitted by BMS on 06/14/2024
Repotrectinib Submitted by BMS on 06/14/2024
Repotrectinib Submitted by BMS on 06/14/2024
Surgery Submitted by Yale New Haven Hospital on 06/26/2024
Surgery Submitted by Yale New Haven Hospital on 06/26/2024
Surgery Submitted by Yale New Haven Hospital on 06/26/2024
Amivantamab-vmjw and lazertinib Submitted by Johnson & Johnson on 06/27/2024
Osimertinib Submitted by Astrazeneca on 06/27/2024
Osimertinib Submitted by Astrazeneca on 06/27/2024
Osimertinib Submitted by Astrazeneca on 06/27/2024
Osimertinib Submitted by Astrazeneca on 06/27/2024
Osimertinib Submitted by Astrazeneca on 06/27/2024
Osimertinib Submitted by Astrazeneca on 06/27/2024
Durvalumab Submitted by AstraZeneca Pharmaceuticals LP and AstraZeneca on 08/15/2024
Amivantamab-vmjw Submitted by Johnson & Johnson on 08/20/2024
Atezolizumab and Hyaluronidase-tqjs Submitted by Genentech on 09/12/2024
Pembrolizumab with Pemetrexed and Platinum Chemotherapy Submitted by Merck & Co., Inc. on 09/19/2024
Nivolumab + Chemotherapy Submitted by BMS on 10/07/2024
Zenocutuzumab-zbco Submitted by Foundation Medicine Inc. on 12/09/2024
Nivolumab + Hyaluronidase-nvhy Submitted by BMS on 01/02/2025
Nivolumab + Hyaluronidase-nvhy Submitted by BMS on 01/03/2025
Nivolumab + Hyaluronidase-nvhy Submitted by BMS on 01/03/2025

Occult Primary Panel

Pembrolizumab Submitted by Merck & Co., Inc. on 06/19/2020
Tumor Mutational Burden (TMB) Submitted by Foundation Medicine, Inc. on 09/15/2020
Galleri Submitted by Grail, Inc. on 05/11/2021
TMB Submitted by Foundation Medicine, Inc. on 05/13/2021
TMB Submitted by Illumina Inc. on 05/13/2021
Dostarlimab-gxly Submitted by GlaxoSmithKline on 08/17/2021
Evaluation and management Submitted by Foundation Medicine, Inc. on 03/22/2022
Nivolumab_ipilimumab Submitted by Bristol-Myers Squibb Company on 04/11/2022
Selpercatinib Submitted by Eli Lilly and Company on 09/21/2022
Erdafitinib Submitted by Janssen Scientific Affairs on 11/15/2023
Repotrectinib Submitted by BMS on 06/14/2024
Repotrectinib Submitted by BMS on 06/14/2024
Repotrectinib Submitted by BMS on 06/14/2024

Older Adult Oncology Panel

Cetirizine hydrochloride Submitted by TerSera Therapeutics on 09/11/2020
Guardant360 CDx Submitted by Guardant Health on 09/30/2020
Cetirizine hydrochloride Submitted by TerSera Therapeutics on 03/05/2021
Cetirizine Submitted by TerSera Therapeutics on 03/05/2021
IV Cetirizine Submitted by Dr. Rex Garland, DO & Dr. Michael S. Blaiss, MD on 10/05/2021
IV Cetirizine Submitted by TerSera Therapeutics on 09/14/2022
IV Cetirizine Submitted by TerSera Therapeutics on 06/14/2023

Ovarian Cancer Panel

Niraparib Submitted by GlaxoSmithKline on 05/19/2020
Nivolumab Submitted by Bristol-Myers Squibb Company on 06/04/2020
Pembrolizumab Submitted by Merck & Co., Inc. on 06/17/2020
myChoice CDx Submitted by Myriad Genetic Laboratories, Inc. on 09/08/2020
OVA1 Multivariate Index Assay Submitted by ASPiRA Women’s Health on 09/10/2020
Guardant360 Submitted by Guardant Health on 09/11/2020
Lurbinectedin Submitted by Jazz Pharmaceuticals Inc. on 09/16/2020
TMB Submitted by Foundation Medicine, Inc. on 09/18/2020
CDx genomic profiling test Submitted by Foundation Medicine, Inc. on 11/06/2020
Selinexor Submitted by Karyopharm Therapeutics on 01/21/2021
Niraparib + Bevacizumab Submitted by GlaxoSmithKline on 03/22/2021
Surveillance Submitted by Sunnybrook Health Sciences Centre on 04/08/2021
Pembrolizumab Submitted by Merck & Co., Inc. on 06/18/2021
Olaparib Submitted by AstraZeneca on 08/06/2021
Dostarlimab-gxly Submitted by GlaxoSmithKline on 08/17/2021
HR Deficiency Submitted by Myriad Genetic Laboratories, Inc. on 09/01/2021
Comprehensive Molecular Testing Submitted by Foundation Medicine, Inc. on 09/09/2021
Cetirizine hydrochloride Submitted by TerSera Therapeutics on 10/07/2021
Olaparib Submitted by AstraZeneca on 10/12/2021
Nivolumab + ipilimumab Submitted by Bristol-Myers Squibb Company on 04/11/2022
Rucaparib Submitted by Clovis Oncology on 06/09/2022
Niraparib + bevacizumab Submitted by GlaxoSmithKline on 06/14/2022
Niraparib Submitted by GlaxoSmithKline on 09/15/2022
Niraparib Submitted by GlaxoSmithKline on 09/16/2022
Cetirizine hydrochloride Submitted by TerSera Therapeutics on 09/16/2022
Selpercatinib Submitted by Eli Lilly and Company on 09/21/2022
HR Deficiency Submitted by Myriad Genetic Laboratories, Inc. on 09/29/2022
ctDNA Submitted by Foundation Medicine, Inc. on 09/29/2022
Pembrolizumab Submitted by eviCore Healthcare on 09/30/2022
Guardant360 Submitted by Guardant Health on 09/30/2022
Mirvetuximab soravtansine Submitted by ImmunoGen, Inc. on 10/03/2022
Mirvetuximab soravtansine + bevacizumab Submitted by ImmunoGen, Inc. on 10/03/2022
Olaparib (+/- bevacizumab) Submitted by AstraZeneca on 10/14/2022
VENTANA FOLR1 RxDx Assay Submitted by Roche Diagnostic Corporation on 02/06/2023
Platinum refractory. Submitted by AdventHealth Cancer Institute on 03/06/2023
Niraparib + bevacizumab Submitted by GlaxoSmithKline on 04/17/2023
Fam-trastuzumab deruxtecan-nxki Submitted by Daiichi-Sankyo, Inc. on 06/05/2023
Oncokb Submitted by Memorial Sloan Kettering Cancer Center on 06/22/2023
Cetirizine hydrochloride for injection Submitted by TerSera Therapeutics on 06/30/2023
Goserelin implant Submitted by TerSera Therapeutics on 07/28/2023
IP carboplatin Submitted by Saitama Medical University International Medical Center on 08/10/2023
Adagrasib Submitted by Mirati Therapeutics, Inc. on 08/11/2023
Olaparib Submitted by Myriad Genetic Laboratories, Inc. on 08/28/2023
Comprehensive genomic profiling (CGP) Submitted by Foundation Medicine, Inc. on 09/01/2023
Mirvetuximab soravtansine-gynx + bevacizumab Submitted by ImmunoGen, Inc. on 09/01/2023
HRD Submitted by AstraZeneca on 09/13/2023
Repotrectinib Submitted by BMS on 06/14/2024
Repotrectinib Submitted by BMS on 06/14/2024

Palliative Care Panel

Interventional Radiologist (IR) consultation Submitted by Society of Interventional Oncology on 07/13/2020
Image Guided Procedures Submitted by Society of Interventional Oncology on 05/23/2023

Pancreatic Adenocarcinoma Panel

Germline testing Submitted by Myriad Genetic Laboratories, Inc. on 06/08/2020
Genomic profiling Submitted by Foundation Medicine, Inc. on 06/12/2020
Pembrolizumab Submitted by Merck & Co., Inc. on 06/17/2020
Gemcitabine/albumin-bound paclitaxel/cisplatin Submitted by Johns Hopkins Medical Insitutions on 06/18/2020
TMB Submitted by Foundation Medicine, Inc. on 06/22/2020
TMB Submitted by Foundation Medicine, Inc. on 09/15/2020
Pralsetinib Submitted by Blueprint Medicines on 09/30/2020
Multi-gene panel testing Submitted by Myriad Genetic Laboratories, Inc. on 05/20/2021
Rucaparib Submitted by Clovis Oncology on 06/03/2021
Pembrolizumab Submitted by Merck & Co., Inc. on 06/18/2021
Methylation-based blood test Submitted by Grail, Inc. on 06/21/2021
sotorasib Submitted by Amgen Inc. on 02/17/2022
nivolumab_ipilimumab Submitted by Bristol-Myers Squibb Company on 04/11/2022
ASTRO link Submitted by American Society for Radiation Oncology on 04/26/2022
Genetics Submitted by Invitae on 05/25/2022
dostarlimab-gxly Submitted by GlaxoSmithKline on 06/28/2022
selpercatinib Submitted by Eli Lilly and Company on 07/01/2022
Pembrolizumab Submitted by Foundation Medicine, Inc. on 07/13/2022
Locoregional therapies Submitted by Society of Interventional Oncology on 07/14/2022
selpercatinib Submitted by Eli Lilly and Company on 09/21/2022
NALIRIFOX Submitted by Ipsen Biopharmaceuticals, Inc. on 01/20/2023
Oncogenic Submitted by Memorial Sloan Kettering Cancer Center on 05/30/2023
liposomal irinotecan Submitted by Ipsen Biopharmaceuticals, Inc. on 09/12/2023
Fam-Trastuzumab Deruxtecan-nxki Submitted by Daiichi Sankyo, Inc. and AstraZeneca on 04/08/2024
Fam-Trastuzumab Deruxtecan-nxki Submitted by Daiichi Sankyo, Inc. and AstraZeneca on 04/08/2024
Fam-Trastuzumab Deruxtecan-nxki Submitted by Daiichi Sankyo, Inc. and AstraZeneca on 04/08/2024
Fam-Trastuzumab Deruxtecan-nxki Submitted by Daiichi Sankyo, Inc. and AstraZeneca on 04/08/2024
Fam-Trastuzumab Deruxtecan-nxki Submitted by Daiichi Sankyo, Inc. and AstraZeneca on 04/08/2024
Fam-Trastuzumab Deruxtecan-nxki Submitted by Daiichi Sankyo, Inc. and AstraZeneca on 04/08/2024
Fam-Trastuzumab Deruxtecan-nxki Submitted by Daiichi Sankyo, Inc. and AstraZeneca on 04/08/2024

Pediatric Acute Lymphoblastic Leukemia Panel

ClonoSEQ® Assay Submitted by Adaptive Biotechnologies on 05/22/2020
clonoSEQ Submitted by Adaptive Biotechnologies on 10/26/2020
MRD Testing Submitted by Adaptive Biotechnologies on 05/19/2021
Asparaginase erwinia chrysanthemi (recombinant) Submitted by Jazz Pharmaceuticals Inc. on 07/02/2021
asparaginase erwinia chrysanthemi Submitted by Jazz Pharmaceuticals Inc. on 04/08/2022
glucarpidase and MTXPK tool Submitted by BTG International on 05/19/2022
Asparaginase erwinia chrysanthemi (recombinant)-rywn Submitted by Jazz Pharmaceuticals Inc. on 11/30/2022
Blinatumomab Submitted by Amgen Inc. on 01/12/2023
IV Cetirizine Submitted by TerSera Therapeutics on 03/22/2023
Blinatumomab Submitted by Amgen Inc. on 09/29/2023

Pediatric Aggressive Mature B-Cell Lymphomas Panel

Glucarpidase MTXPK Submitted by BTG International on 05/26/2022

Pediatric Central Nervous System Cancers Panel

Repotrectinib Submitted by BMS on 06/14/2024

Pediatric Hodgkin Lymphoma Panel

Pembrolizumab Submitted by Merck & Co., Inc. on 10/15/2020
brentuximab vedotin + doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide (BV-AVE-PC) Submitted by Seagen Inc on 12/07/2022
N-AVD Submitted by Bristol-Myers Squibb Company on 07/24/2023

Prevention and Treatment of Cancer-Related Infections Panel

ASCENIV® Submitted by ADMA Biologics on 09/25/2020
Temperature Monitoring Submitted by Blue Spark Technologies on 10/25/2022

Prostate Cancer Early Detection Panel

Germline Genetic Testing Submitted by Myriad Genetic Laboratories, Inc. on 09/18/2020
miR Scientific Sentinel Prostate Cancer Test Platform Submitted by Columbia University Medical Center on 09/23/2020
miR Scientific Sentinel™ Prostate Cancer Test Platform Submitted by miR Scientific on 09/29/2020
ExactVu 29MHz Micro-Ultrasound system Submitted by Exact Imaging Inc. on 11/10/2020
IsoPSA Submitted by Cleveland Diagnostics, Inc. on 09/15/2021
Stockholm3 Submitted by Karolinska Institutet and A3P Biomedical AB on 09/19/2021
miR Scientific Sentinel Submitted by Vanderbilt University Medical Center on 09/20/2021
miR Scientific Sentinel_2 Submitted by Vanderbilt University Medical Center on 09/20/2021
ExoDx Prostate Test Submitted by ExosomeDx on 10/03/2022
MyProstateScore (MPS) Submitted by LynxDx on 06/07/2023
Stockholm3 Submitted by Karolinska Institutet and A3P Biomedical AB on 08/18/2023

Prostate Cancer Panel

Laser Focal Therapy Submitted by Halo Diagnostics on 06/06/2020
CGP Submitted by Foundation Medicine, Inc. on 08/28/2020
TMB Submitted by Foundation Medicine, Inc. on 09/15/2020
Plasma ctDNA test Submitted by AstraZeneca on 12/09/2020
Relugolix Submitted by Myovant Sciences, Inc. on 12/23/2020
cabazitaxel Submitted by Sanofi on 01/29/2021
PSMA PET_CT Submitted by UCLA on 02/24/2021
apalutamide Submitted by Janssen Scientific Affairs, LLC on 02/25/2021
relugolix Submitted by Myovant Sciences, Inc. on 03/19/2021
Talazoparib Submitted by Pfizer Inc. on 03/23/2021
CGP Submitted by Guardant Health on 04/09/2021
Germline Testing Submitted by Myriad Genetic Laboratories, Inc. on 04/13/2021
Molecular Marker Submitted by Myriad Genetic Laboratories, Inc. on 04/13/2021
Genomic Profiling Submitted by Foundation Medicine, Inc. on 04/14/2021
Oncotype DX GPS Submitted by Exact Sciences Inc. on 04/15/2021
Oncotype DX GPS Submitted by Exact Sciences Inc. on 04/15/2021
Decipher Submitted by Decipher Biosciences Inc. on 04/16/2021
relugolix Submitted by TerSera Therapeutics on 04/26/2021
fluciclovine Submitted by Blue Earth Diagnostics on 05/06/2021
Cabazitaxel Submitted by Sanofi on 06/15/2021
Pembrolizumab Submitted by Merck & Co., Inc. on 06/17/2021
piflufolastat F 18 Submitted by Lantheus Holdings on 06/28/2021
olaparib plus abiraterone Submitted by AstraZeneca on 02/17/2022
Darolutamide Submitted by Bayer HealthCare on 02/18/2022
Pluvicto Submitted by Novartis Pharmaceuticals Corporation on 03/23/2022
Oncotype DX Submitted by Exact Sciences Inc. on 03/30/2022
Decipher Submitted by Veracyte, Inc. on 04/01/2022
Genomic Profiling Submitted by Foundation Medicine, Inc. on 04/01/2022
miR Sentinel Submitted by miR Scientific on 04/01/2022
Talazoparib Submitted by Pfizer Inc. on 04/01/2022
ATM germline Submitted by Ambry Genetics on 04/05/2022
molecular and biomarker analysis Submitted by Myriad Genetic Laboratories, Inc. on 04/08/2022
nivolumab ipilimumab Submitted by Bristol-Myers Squibb Company on 04/11/2022
olaparib plus abiraterone Submitted by AstraZeneca on 06/03/2022
ArteraAI Prostate Test Submitted by Artera, Inc on 06/12/2022
Cabozantinib with atezolizumab Submitted by Exelixis Inc. on 07/22/2022
BRCA testing for high-risk prostate cancer Submitted by Linda W. Wilson M.D. INC on 09/29/2022
Artera AI Submitted by Artera, Inc on 02/21/2023
Molecular Assay Submitted by Veracyte, Inc. on 04/07/2023
Apalutamide with ADT Submitted by Janssen Scientific Affairs, LLC and UCSF Helen Diller Family Comprehensive Cancer Center on 04/11/2023
Germline Testing Modifications Submitted by AliveAndKickn, Ambry Genetics, GeneDx, Illumina, Myriad Genetics, Quest Diagnostics, and Volpara Health and FORCE on 04/13/2023
Relugolix Submitted by Myovant Sciences, Inc. and Pfizer Inc. on 04/18/2023
FORMULA-509 Submitted by Dana-Farber/Brigham Cancer Center & Harvard Medical School on 04/19/2023
Molecular Marker Submitted by Myriad Genetic Laboratories, Inc. on 04/20/2023
Ablation Types Submitted by Society of Interventional Radiology on 04/20/2023
Darolutamide Submitted by Bayer HealthCare on 04/20/2023
Comprehensive Genomic Profiling (CGP) Submitted by Foundation Medicine, Inc. on 04/21/2023
flotufolastat F 18 Submitted by Blue Earth Diagnostics on 05/30/2023
Olaparib/abiraterone for mCRPC and BRCAm Submitted by AstraZeneca on 06/01/2023
talazoparib/enzalutamide for adult patients with HRRm mCRPC Submitted by Pfizer Inc. on 06/26/2023
Niraparib/abiraterone Submitted by Janssen Scientific Affairs, LLC on 08/14/2023
F18 Flotufolastat Submitted by Lantheus on 10/13/2023
Cabazitaxel Submitted by Sanofi on 11/01/2023
Apalutamide Submitted by Janssen Scientific Affairs on 11/15/2023
EMBARK Submitted by Astellas Pharma Inc. and Pfizer Inc. on 12/08/2023
Apalutamide with ADT Submitted by UCSF and Janssen Scientific Affairs, LLC on 02/01/2024
Abiraterone Submitted by UnitedHealthcare on 02/09/2024
Focused Ultrasound and Cryoablation Submitted by University of Pennsylvania, Society of Interventional Oncology and Society of Interventional Radiology on 04/10/2024
Focused Ultrasound and Cryoablation Submitted by University of Pennsylvania, Society of Interventional Oncology and Society of Interventional Radiology on 04/10/2024
Focused Ultrasound and Cryoablation Submitted by University of Pennsylvania, Society of Interventional Oncology and Society of Interventional Radiology on 04/10/2024
Enzalutamide Submitted by Royal Adelaide Hospital on 04/13/2024
Somatic Tumor molecular profiling Submitted by Access to Comprehensive Genomic Profiling (ACGP), Illumina Inc., Johnson & Johnson, LabCorp, Loxo@Lilly, Merck & Co., Inc., NeoGenomics, Roche Diagnostic Corporation, Tempus and ThermoFisher Scientific on 04/16/2024
Somatic Tumor Testing Submitted by Access to Comprehensive Genomic Profiling (ACGP), Illumina Inc., Johnson & Johnson, LabCorp, Loxo@Lilly, Merck & Co., Inc., NeoGenomics, Roche Diagnostic Corporation, Tempus and ThermoFisher Scientific on 04/16/2024
ctDNA Submitted by Access to Comprehensive Genomic Profiling (ACGP), Illumina Inc., Johnson & Johnson, LabCorp, Loxo@Lilly, Merck & Co., Inc., NeoGenomics, Roche Diagnostic Corporation, Tempus and ThermoFisher Scientific on 04/16/2024
Comprehensive Genomic Profiling Submitted by Access to Comprehensive Genomic Profiling (ACGP), Illumina Inc., Johnson & Johnson, LabCorp, Loxo@Lilly, Merck & Co., Inc., NeoGenomics, Roche Diagnostic Corporation, Tempus and ThermoFisher Scientific on 04/16/2024
Pembrolizumab Submitted by Access to Comprehensive Genomic Profiling (ACGP), Illumina Inc., Johnson & Johnson, LabCorp, Loxo@Lilly, Merck & Co., Inc., NeoGenomics, Roche Diagnostic Corporation, Tempus and ThermoFisher Scientific on 04/16/2024
Selpercatinib/ Larotrectinib/ Dabrafenib and Trametinib Submitted by Access to Comprehensive Genomic Profiling (ACGP), Illumina Inc., Johnson & Johnson, LabCorp, Loxo@Lilly, Merck & Co., Inc., NeoGenomics, Roche Diagnostic Corporation, Tempus and ThermoFisher Scientific on 04/16/2024
Comprehensive Genomic Profiling Submitted by Access to Comprehensive Genomic Profiling (ACGP), Illumina Inc., Johnson & Johnson, LabCorp, Loxo@Lilly, Merck & Co., Inc., NeoGenomics, Roche Diagnostic Corporation, Tempus and ThermoFisher Scientific on 04/16/2024
Dutasteride and Finasteride Submitted by Reboot Rx on 04/16/2024
Simon Level of Evidence Submitted by Myriad Genetics on 04/17/2024
Cell Cycle Progression (CCP) Assay Submitted by Myriad Genetics on 04/17/2024
Cell Cycle Progression (CCP) Assay Submitted by Myriad Genetics on 04/17/2024
Cycle Progression (CCP) Assay Submitted by Myriad Genetics on 04/17/2024
Enzalutamide Submitted by Astellas Pharma on 04/18/2024
Dutasteride and Finasteride Submitted by Reboot Rx on 04/18/2024
Dutasteride and Finasteride Submitted by Reboot Rx on 04/18/2024
Brachytherapy Submitted by Cedars Sinai Medical center on 04/18/2024
Brachytherapy Submitted by Cedars Sinai Medical center on 04/18/2024
PARP inhibitors Submitted by Foundation Medicine Inc. on 04/19/2024
ctDNA Submitted by Foundation Medicine Inc. on 04/19/2024
Gene Mutation Testing Submitted by Foundation Medicine Inc. on 04/19/2024
Enzalutamide Submitted by Astellas Pharma and Pfizer Inc. on 05/06/2024
Repotrectinib Submitted by BMS on 06/14/2024
Repotrectinib Submitted by BMS on 06/14/2024
ctDNA Submitted by Pfizer on 06/25/2024
Cabazitaxel Submitted by Sanofi on 06/28/2024
Niraparib with Abiraterone Submitted by eviCore on 09/04/2024
Darolutamide Submitted by Bayer Pharmaceuticals on 10/14/2024

Skin Cancers Excluding Melanoma Panel

Pembrolizumab Submitted by Merck & Co., Inc. on 06/25/2020
Pembrolizumab for Squamous Cell Skin Cancer Submitted by Merck & Co., Inc. on 06/25/2020
Cemiplimab Submitted by Regeneron Pharmaceuticals, Inc. on 07/08/2020
Pembrolizumab for Squamous Cell Skin Cancer Submitted by Merck & Co., Inc. on 09/14/2020
Cemiplimab Submitted by Regeneron Pharmaceuticals, Inc. on 02/10/2021
Sonidegib Submitted by Sunesis Pharmaceuticals, Inc. on 02/26/2021
Avelumab Submitted by Pfizer Inc. on 04/08/2021
Pembrolizumab for Squamous Cell Skin Cancer Submitted by Merck & Co., Inc. on 07/13/2021
Radiation Therapy Submitted by American Society for Radiation Oncology on 03/29/2022
40-GEP Submitted by Castle Biosciences on 04/08/2022
IGSRT Submitted by SkinCure Oncology on 04/13/2022
40-GEP Submitted by University of Rochester Medical Center, Department of Dermatology on 04/19/2022
ASTRO Link Submitted by American Society for Radiation Oncology on 04/26/2022
Selpercatinib Submitted by Eli Lilly and Company on 09/21/2022
Cemiplimab-rwlc Submitted by Regeneron Pharmaceuticals, Inc. on 10/03/2022
40-GEP Submitted by Castle Biosciences on 10/18/2022
IGRT for Squamous Cell Skin Cancer Submitted by eviCore Healthcare on 01/03/2023
Avelumab for Merkel Cell Carcinoma Submitted by EMD Serono on 02/03/2023
Nivolumab for Merkel Cell Carcinoma Submitted by Bristol-Myers Squibb Company on 02/14/2023
Retifanlimab-dlwr Submitted by Incyte Corporation on 03/23/2023
GEP tests for Squamous Cell Skin Cancer Submitted by Castle Biosciences on 04/03/2023
IGSRT Submitted by SkinCure Oncology on 04/12/2023
40-GEP test for Squamous Cell Skin Cancer Submitted by Castle Biosciences on 04/27/2023
40-GEP for Squamous Cell Skin Cancer Submitted by SkinCure Oncology on 05/01/2023
Retifanlimab-dlwr Submitted by Incyte Corporation on 11/06/2023
Retifanlimab-dlwr Submitted by Incyte Corporation on 11/06/2023
Retifanlimab-dlwr Submitted by Incyte Corporation on 11/06/2023
nivolumab Submitted by Bristol-Myers Squibb Company on 07/18/2024
nivolumab + hyaluronidase-nvhy Submitted by BMS on 01/03/2025

Small Cell Lung Cancer Panel

Lurbinectedin Submitted by Jazz Pharmaceuticals Inc. on 06/15/2020
Nivolumab Submitted by Bristol-Myers Squibb Company on 12/29/2020
Trilaciclib Submitted by G1 Therapeutics on 02/12/2021
Atezolizumab Submitted by Genentech, Inc. on 03/16/2021
Pembrolizumab Submitted by Merck & Co., Inc. on 03/31/2021
Radiation Therapy Submitted by American Society for Radiation Oncology on 03/04/2022
Nivolumab in combination with ipilimumab for patients with advanced or metastatic tTMB-H solid tumors Submitted by Bristol-Myers Squibb Company on 04/11/2022
CGP Submitted by Foundation Medicine Inc. on 03/21/2024
Amifampridine (Firdapse) Submitted by Catalyst on 03/25/2024
Amifampridine (Firdapse) Submitted by Catalyst on 03/25/2024
Tislelizumab with Etoposide Submitted by BeiGene USA on 03/27/2024
Tarlatamab-dlle Submitted by Amgen on 05/17/2024

Soft Tissue Sarcoma Panel

Ripretinib Submitted by Deciphera Pharmaceuticals, Inc. on 05/18/2020
Footnotes Submitted by Society of Interventional Oncology on 06/08/2020
Cabozantinib Submitted by Exelixis Inc. on 06/10/2020
Pembrolizumab Submitted by Merck & Co., Inc. on 06/17/2020
Comprehensive genomic profiling (CGP) Submitted by Foundation Medicine, Inc. on 06/17/2020
Ripretinib Submitted by Deciphera Pharmaceuticals, Inc. on 06/19/2020
Tumor Mutational Burden (TMB) Submitted by Foundation Medicine, Inc. on 06/23/2020
Ripretinib Submitted by Deciphera Pharmaceuticals, Inc. on 08/17/2020
Submission request for review of selinexor in soft tissue sarcoma. Submitted by American Society for Radiation Oncology and Karyopharm Therapeutics on 04/29/2021
Update principles of Ancillary Techniques to include statement regarding molecular genetic testing. Submitted by Foundation Medicine, Inc. on 05/14/2021
Submission for 2021 NCCN Soft Tissue Sarcoma Guideline gaps relative to radiation therapy Submitted by American Society for Radiation Oncology on 06/11/2021
Request for addition of regorafenib an open-label single-arm phase II study for the treatment of angiosarcoma. Submitted by Bayer HealthCare on 08/02/2021
Update to Submission for Ripretinib Dose Escalation to 150 mg Twice Daily (BID) Submitted by Deciphera Pharmaceuticals, Inc. on 08/16/2021
Request the inclusion of pembrolizumab in combination with axitinib as a treatment option for patients with advanced sarcomas including alveolar soft part sarcoma. Submitted by Merck & Co., Inc. on 08/27/2021
Submission for FYARRO (sirolimus protein-bound particles for injectable suspension) (albumin-bound) Submitted by Aadi Bioscience on 11/26/2021
Ponatinib Submitted by Takeda Oncology on 04/08/2022
Request to include nivolumab in combination with ipilimumab as a treatment option for patients with tissue TMB-H (tTMB-H) Submitted by Bristol-Myers Squibb Company on 04/11/2022
Selinexor Submitted by Karyopharm Therapeutics on 04/11/2022
Atezolizumab for ASPS Submitted by Genentech, Inc. on 06/15/2022
Crizotinib Submitted by Pfizer Inc. on 07/14/2022
Request hepatic artery embolization Submitted by Society of Interventional Oncology on 08/11/2022
Ripretinib as a second line treatment option Submitted by Deciphera Pharmaceuticals, Inc. on 08/11/2022
Update embolization procedure and consider additional footnotes Submitted by Society of Interventional Oncology on 08/11/2022
Update statement regarding molecular genetic testing Submitted by Foundation Medicine, Inc. on 08/16/2022
Selpercatinib Submitted by Eli Lilly and Company on 09/21/2022
Request to include lenvatinib in combination with eribulin as a treatment option Submitted by Eisai Inc. on 10/17/2022
Pembrolizumab MSI-H or dMMR Submitted by Merck & Co., Inc. on 03/30/2023
Pembrolizumab MSI-H or dMMR Submitted by Merck & Co., Inc. on 03/30/2023
Oncogenic OncoKB Submitted by Memorial Sloan Kettering Cancer Center on 06/23/2023
Comprehensive genomic profiling Submitted by Foundation Medicine, Inc. on 08/24/2023
Update embolization procedure and consider additional footnotes Submitted by Society of Interventional Oncology on 08/25/2023
Eribulin in combination with gemcitabine Submitted by Eisai Inc. on 08/28/2023
Avapritinib Submitted by Blueprint Medicines on 09/07/2023
Nirogacestat Submitted by Springworks Therapeutics on 11/27/2023
Nirogacestat Submitted by Springworks Therapeutics on 11/27/2023
Repotrectinib Submitted by BMS on 06/14/2024
Repotrectinib Submitted by BMS on 06/14/2024
Repotrectinib Submitted by BMS on 06/14/2024
Repotrectinib Submitted by BMS on 06/14/2024
Repotrectinib Submitted by BMS on 06/14/2024
Repotrectinib Submitted by BMS on 06/14/2024
Repotrectinib Submitted by BMS on 06/14/2024
Repotrectinib Submitted by BMS on 06/14/2024
Atezolizumab and Hyaluronidase-tqjs Submitted by Genentech on 09/12/2024

Survivorship Panel

Head and neck lymphedema Submitted by Vanderbilt University School of Nursing on 11/09/2020
Pneumatic compression for lymphedema Submitted by Vanderbilt University School of Nursing on 11/09/2020
Intermittent fasting data Submitted by Moffitt Cancer Center/ University of South Florida on 01/15/2021
Web-based Survivorship Care Plan Submitted by OncoLink on 08/04/2021
Zoster Vaccine Recombinant, Adjuvanted [RZV]) Submitted by GlaxoSmithKline on 10/23/2021
Lymphedema management Submitted by Yale New Haven Health - Greenwich Hospital on 09/23/2022
Predictive diagnostic assay Submitted by Biotheranostics on 08/28/2023

T-Cell/Primary Cutaneous Lymphomas Panel

Duvelisib Submitted by Verastem, Inc. on 06/11/2020
Leucovorin Submitted by Acrotech Biopharma LLC on 06/12/2020
ENKTL Submitted by Sun Yat-sen University Cancer Center on 06/14/2020
clonoSEQ® Assay Submitted by Adaptive Biotechnologies on 06/19/2020
Alectinib Submitted by Genentech, Inc. on 07/19/2021
Romidepsin Submitted by Bristol-Myers Squibb Company on 12/03/2021
Mechlorethamine gel Submitted by Helsinn Therapeutics, Inc. on 12/09/2022
Cetirizine Submitted by TerSera Therapeutics on 03/15/2023
Cetirizine Submitted by TerSera Therapeutics on 04/03/2023
Brigatinib Submitted by Takeda Oncology on 06/20/2023
Cetirizine Hydrochloride for Injection Submitted by TerSera on 04/17/2024
Methotrexate, Etoposide, Dexamethasone, and Pegaspargase Submitted by Xinhua Hospital on 06/09/2024
Denileukin diftitox-cxdl Submitted by Citius Pharma on 07/01/2024
Denileukin diftitox-cxdl Submitted by Citius Pharma on 07/01/2024
Denileukin diftitox-cxdl Submitted by Citius Pharma on 07/01/2024

Testicular Cancer Panel

Pembrolizumab Submitted by Merck & Co., Inc. on 06/17/2020
TMB Submitted by Illumina Inc. on 05/13/2021
Cabazitaxel Submitted by Sanofi on 11/04/2021
Nivolumab + Ipilimumab Submitted by Bristol-Myers Squibb Company on 04/11/2022
Comprehensive Genomic Profiling + Circulating Tumor DNA (ctDNA) Assay Submitted by Guardant Health on 05/18/2022
Pembrolizumab References Submitted by Merck & Co., Inc. on 03/30/2023
MRI Surveillance Submitted by Isaac Rapelje on 05/15/2023

Thyroid Carcinoma Panel

Pembrolizumab Submitted by Merck & Co., Inc. on 06/17/2020
Tumor Mutational Burden (TMB) Submitted by Foundation Medicine, Inc. on 06/29/2020
Pralsetinib Submitted by Blueprint Medicines on 12/01/2020
Cabozantinib Submitted by Exelixis Inc. on 09/21/2021
Lenvatinib and pembrolizumab Submitted by Eisai Inc. on 09/24/2021
Diagnostic Procedures Submitted by Myriad Genetic Laboratories, Inc. on 09/24/2021
Molecular Diagnostics Submitted by Veracyte, Inc. on 10/06/2021
CGP Submitted by Illumina Inc. on 11/02/2021
Cabozantinib Submitted by Exelixis Inc. on 06/03/2022
Pembrolizumab Submitted by Merck & Co., Inc. on 04/04/2023
Oncogenic mutations in RET Submitted by Memorial Sloan Kettering Cancer Center on 05/30/2023
Personal and family history screening Submitted by Myriad Genetic Laboratories, Inc. on 07/31/2023
Selpercatinib Submitted by Eli Lilly and Company on 10/23/2023
Repotrectinib Submitted by BMS on 06/14/2024
Repotrectinib Submitted by BMS on 06/14/2024
Repotrectinib Submitted by BMS on 06/14/2024
Repotrectinib Submitted by BMS on 06/14/2024
Repotrectinib Submitted by BMS on 06/14/2024
Repotrectinib Submitted by BMS on 06/14/2024
Repotrectinib Submitted by BMS on 06/14/2024
Repotrectinib Submitted by BMS on 06/14/2024
Repotrectinib Submitted by BMS on 06/14/2024

Wilms Tumor Panel